<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants - Aher, SM - 2020 | Cochrane Library</title> <meta content="Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants - Aher, SM - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004868.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants - Aher, SM - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004868.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004868.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants" name="citation_title"/> <meta content="Sanjay M Aher" name="citation_author"/> <meta content="Neocare Hospital" name="citation_author_institution"/> <meta content="ahersm@googlemail.com" name="citation_author_email"/> <meta content="Arne Ohlsson&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD004868.pub6" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/01/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004868.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004868.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004868.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia, Neonatal [blood, prevention &amp; control]; *Erythrocyte Transfusion; Hematinics [administration &amp; dosage, *therapeutic use]; Infant, Low Birth Weight [*blood]; Infant, Premature [*blood]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004868.pub6&amp;doi=10.1002/14651858.CD004868.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="1pyM3CVc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004868\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004868\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","zh_HANS","ja","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004868.pub6",title:"Late erythropoiesis\\u2010stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants",firstPublishedDate:"Jan 28, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004868.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004868.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004868.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004868.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004868.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004868.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004868.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004868.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004868.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004868.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3162 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004868.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-sec-0089"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/appendices#CD004868-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/table_n/CD004868StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/table_n/CD004868StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/information#CD004868-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sanjay M Aher</a></li> <li class="author custom-tooltip" title="Deceased"><a href="/cdsr/doi/10.1002/14651858.CD004868.pub6/information#CD004868-cr-0003">Arne Ohlsson</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/information/en#CD004868-sec-0112">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 January 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004868.pub6">https://doi.org/10.1002/14651858.CD004868.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004868-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004868-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004868-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004868-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004868-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004868-abs-0001" lang="en"> <section id="CD004868-sec-0001"> <h3 class="title" id="CD004868-sec-0001">Background</h3> <p>Preterm infants have low plasma levels of erythropoietin (EPO), providing a rationale for the use of erythropoiesis‐stimulating agents (ESAs) to prevent or treat anaemia. Darbepoetin (Darbe) and EPO are currently available ESAs. </p> </section> <section id="CD004868-sec-0002"> <h3 class="title" id="CD004868-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of late initiation of ESAs, between eight and 28 days after birth, in reducing the use of red blood cell (RBC) transfusions in preterm or low birth weight infants. </p> </section> <section id="CD004868-sec-0003"> <h3 class="title" id="CD004868-sec-0003">Search methods</h3> <p>We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2018, Issue 5), MEDLINE via PubMed (1966 to 5 June 2018), Embase (1980 to 5 June 2018), and CINAHL (1982 to 5 June 2018). We searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi‐randomised trials. </p> </section> <section id="CD004868-sec-0004"> <h3 class="title" id="CD004868-sec-0004">Selection criteria</h3> <p>Randomised or quasi‐randomised controlled trials of late initiation of EPO treatment (started at ≥ eight days of age) versus placebo or no intervention in preterm (&lt; 37 weeks) or low birth weight (&lt; 2500 grams) neonates. </p> </section> <section id="CD004868-sec-0005"> <h3 class="title" id="CD004868-sec-0005">Data collection and analysis</h3> <p>We performed data collection and analyses in accordance with the methods of the Cochrane Neonatal Review Group. We used the GRADE approach to assess the quality of the evidence. </p> </section> <section id="CD004868-sec-0006"> <h3 class="title" id="CD004868-sec-0006">Main results</h3> <p>We include 31 studies (32 comparisons) randomising 1651 preterm infants. Literature searches in 2018 identified one new study for inclusion. No new on‐going trials were identified and no studies used darbepoetin. </p> <p>Most included trials were of small sample size. The meta‐analysis showed a significant effect on the use of one or more RBC transfusions (21 studies (n = 1202); typical risk ratio (RR) 0.72, 95% confidence interval (CI) 0.65 to 0.79; typical risk difference (RD) ‐0.17, 95% CI ‐0.22 to ‐0.12; typical number needed to treat for an additional beneficial outcome (NNTB) 6, 95% CI 5 to 8). There was moderate heterogeneity for this outcome (RR I² = 66%; RD I² = 58%). The quality of the evidence was very low. We obtained similar results in secondary analyses based on different combinations of high/low doses of EPO and iron supplementation. There was no significant reduction in the total volume (mL/kg) of blood transfused per infant (typical mean difference (MD) ‐1.6 mL/kg, 95% CI ‐5.8 to 2.6); 5 studies, 197 infants). There was high heterogeneity for this outcome (I² = 92%). There was a significant reduction in the number of transfusions per infant (11 studies enrolling 817 infants; typical MD ‐0.22, 95% CI ‐0.38 to ‐0.06). There was high heterogeneity for this outcome (I² = 94%). </p> <p>Three studies including 404 infants reported on retinopathy of prematurity (ROP) (all stages or stage not reported), with a typical RR 1.27 (95% CI 0.99 to 1.64) and a typical RD of 0.09 (95% CI ‐0.00 to 0.18). There was high heterogeneity for this outcome for both RR (I² = 83%) and RD (I² = 82%). The quality of the evidence was very low.Three trials enrolling 442 infants reported on ROP (stage ≥ 3). The typical RR was 1.73 (95% CI 0.92 to 3.24) and the typical RD was 0.05 (95% CI ‐0.01 to 0.10). There was no heterogeneity for this outcome for RR (I² = 18%) but high heterogeneity for RD (I² = 79%). The quality of the evidence was very low.There were no significant differences in other clinical outcomes including mortality and necrotising enterocolitis. For the outcomes of mortality and necrotising enterocolitis, the quality of the evidence was moderate. Long‐term neurodevelopmental outcomes were not reported. </p> </section> <section id="CD004868-sec-0007"> <h3 class="title" id="CD004868-sec-0007">Authors' conclusions</h3> <p>Late administration of EPO reduces the use of one or more RBC transfusions, the number of RBC transfusions per infant (&lt; 1 transfusion per infant) but not the total volume (mL/kg) of RBCs transfused per infant. Any donor exposure is likely not avoided as most studies included infants who had received RBC transfusions prior to trial entry. Late EPO does not significantly reduce or increase any clinically important adverse outcomes except for a trend in increased risk for ROP. Further research of the use of late EPO treatment, to prevent donor exposure, is not indicated. Research efforts should focus on limiting donor exposure during the first few days of life in sick neonates, when RBC requirements are most likely to be required and cannot be prevented by late EPO treatment. The use of satellite packs (dividing one unit of donor blood into many smaller aliquots) may reduce donor exposure. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004868-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004868-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004868-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004868-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004868-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004868-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004868-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004868-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004868-abs-0003" lang="en"> <h3>Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effectiveness and safety of late initiation of erythropoiesis‐stimulating agents treatment between eight and 28 days after birth, for reducing the use of red blood cell (RBC) transfusions in preterm or low birth weight infants. </p> <p><b>Background</b> </p> <p>The percentage of circulating red blood cells (haematocrit) falls after birth in all infants. This is particularly true in preterm infants due to their poor response to anaemia and to the amount of blood that is drawn for necessary testing. Low plasma levels of erythropoietin (EPO), a substance in the blood that stimulates red blood cell production in preterm infants, provide a rationale for the use of erythropoiesis‐stimulating agents (EPO and darbepoetin) to prevent or treat anaemia. </p> <p><b>Search date</b> </p> <p>The evidence is current to 5 June 2018.</p> <p><b>Study characteristics</b> </p> <p>To date, 1651 infants (between eight and 28 days of age) born preterm have been enrolled in 31 studies of late administration of EPO to reduce the use of red blood cell transfusions and to prevent donor exposure. </p> <p>There were no studies that used darbepoetin.</p> <p><b>Study funding sources</b> </p> <p>We have not received any funding for this review and we have no conflicts of interest to declare. </p> <p><b>Key results</b> </p> <p>The risk of receiving red blood transfusion is reduced following initiation of EPO treatment. However, the overall benefit of EPO is reduced as many of these infants had been exposed to donor blood prior to entry into the trials. Treatment with late EPO did not have any important effects on death or common complications of preterm birth, except for trends towards an increased risk for retinopathy of prematurity. Retinopathy of prematurity is a disease of the eye affecting infants born preterm. It is thought to be caused by disorganised growth of retinal blood vessels, which may result in scarring and retinal detachment. Retinopathy of prematurity can be mild and may resolve spontaneously, but it may lead to blindness in serious cases. </p> <p><b>Quality of the evidence</b> </p> <p>The study quality varied and important information regarding the random sequence generation and whether the allocation was concealed or not was often missing. Sample sizes were small and long‐term outcomes (18 to 24 months of corrected age) were not reported. The quality of the evidence was very low for the outcomes of "use of one or more red blood cell transfusions," "retinopathy of prematurity (all stages or stage not reported)" and for "retinopathy of prematurity (stage ≥ 3)". For the outcomes of "necrotising enterocolitis" and "mortality", the quality of the evidence was moderate. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004868-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004868-sec-0095"></div> <h3 class="title" id="CD004868-sec-0096">Implications for practice</h3> <section id="CD004868-sec-0096"> <p>Late EPO administration results in a reduction in the use of one or more red blood cell transfusions following initiation of therapy. It minimally reduces the number of red blood cell transfusions per infant. It is not associated with reductions in mortality or other neonatal morbidities. The use of late EPO is not associated with any short‐term serious side effects except for a possible association with retinopathy of prematurity (ROP) stage 3 or higher. A large proportion of extremely low BW/preterm neonates require red blood cell transfusions during the first few days of life, when neither early nor late EPO administration could possibly have an impact. The decision to use late EPO will depend on the baseline rate of red blood cell transfusions in this population in a specific neonatal intensive care unit, the costs, the associated pain, and the values assigned to the clinical outcomes. Other means of reducing the need for red blood cell transfusions should be considered, including reduced blood sampling, and the use of 'satellite packs' from directed or universal donors. </p> </section> <h3 class="title" id="CD004868-sec-0097">Implications for research</h3> <section id="CD004868-sec-0097"> <p>There is no need for further research to assess the effectiveness of the late use of EPO in reducing red blood cell transfusions. Its effectiveness has been established in populations that were exposed to donor blood prior to study entry, minimising the clinical importance of this effect. Future research should focus on strategies to minimise red blood cell donor exposure (using multiple aliquots from a properly tested single donor) during the first week of life, when the likelihood of need for red blood cell transfusions is at its peak. Such strategies, in combination with late EPO treatment, may reduce further donor exposure in early infancy. All ongoing and planned studies should monitor the incidence of retinopathy of prematurity. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004868-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004868-sec-0015"></div> <div class="table" id="CD004868-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Late EPO compared with placebo or no intervention for complications of preterm birth ‐ primary and secondary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants</b> with low birth weight </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: Late EPO</b> </p> <p><b>Comparison: Placebo or no intervention</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>EPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of one or more red blood cell transfusions (low and high dose of EPO) during initial hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.72</b> (0.65 to 0.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1202<br/> (21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in 16 of the studies, about allocation concealment in 17 of the studies and about blinding (performance bias and detection bias) in 11 of the studies. We downgraded the quality of the evidence by one step.<br/> Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 66% and for<br/> the typical RD 58% (both moderate heterogeneity). We downgraded the quality of the evidence by one step.<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the large sample size (n = 1202), the point estimate was precise with a narrow 95% CI.<br/> Presence of publication bias: The funnel plot was asymmetrical ‐ we downgraded the quality of the evidence by one step. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>603 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>434 per 1000</b><br/> (392 to 477) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising Enterocolitis ≥ Bell's stage 2 during initial hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.88</b> </p> <p>(0.45 to 1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>656<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in two of the studies, about allocation concealment in three of the studies and about blinding (performance bias and detection bias) in one of the studies. We downgraded the quality of the evidence by one step. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for both the typical RR and for the typical RD was 0% (both no heterogeneity).<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the sample size (n = 656), the point estimate was quite precise with a narrow 95% CI.<br/> Presence of publication bias: As only six studies were included in the analyses we did not perform a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (23 to 88) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality during initial hospital stay (all causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.82</b> (0.49 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>767<br/> (14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in 11 of the studies, about allocation concealment in 7 of the studies and about blinding (performance bias and detection bias) in six of the studies. We downgraded the quality of the evidence by one step.<br/> Heterogeneity/Consistency: I<sup>2</sup> for the typical RR and for the RD was 0% (both no heterogeneity).<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the large sample size (n = 1202), the point estimate was precise with a narrow 95% CI.<br/> Presence of publication bias: The funnel plot was symmetrical. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> <p>(31 to 88)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Retinopathy of prematurity (all stages or stage not reported) during initial hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.27 (0.99 to 1.64)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>404<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in two of the studies, about allocation concealment in none of the studies, and about blinding (performance bias and detection bias) in two of the studies. We downgraded the quality of the evidence by one step.<br/> Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 83% and for the typical RD 82% (both high heterogeneity). We downgraded the quality of the evidence by one step.<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the small sample size (n = 404 ), the point estimate was not precise. We downgraded the quality of the evidence by one step.<br/> Presence of publication bias: As there was only three studies included we did not perform a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>417 per 1000</b><br/> (325 to 538) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Retinopathy of prematurity (stage ≥ 3) during initial hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.73 (0.92 to 3.24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>442<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in two of the studies, about allocation concealment in none of the studies, and about blinding (performance bias and detection bias) in two of the studies. We downgraded the quality of the evidence by one step.<br/> Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 18% (no heterogeneity) and for<br/> the typical RD 79% (high heterogeneity). We downgraded the quality of the evidence by one step.<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the small sample size (n = 442 ), the point estimate was not precise. We downgraded the quality of the evidence by one step.<br/> Presence of publication bias: As there was only three studies included we did not perform a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b><br/> (58 to 203) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>EPO</b> : erythropoietin; <b>I<sup>2</sup> </b> = I‐squared; <b>NICU</b> : Neonatal Intensive Care Unit; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004868-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004868-sec-0016"></div> <section id="CD004868-sec-0017"> <h3 class="title" id="CD004868-sec-0017">Description of the condition</h3> <p>After birth, the haemoglobin (a hemoprotein composed of globin and heme that gives red blood cells heir characteristic colour; function primarily to transport oxygen from the lungs to the body tissues) concentration of newborn infants falls to minimal levels of 11 g/dL in term infants by eight to 12 weeks of age, and to 7.0 to 10.0 g/dL in preterm infants by six weeks of age (<a href="./references#CD004868-bbs2-0072" title="StockmanJA3rd , OskiFA . Physiological anaemia of infancy and the anaemia of prematurity. Clinics in Hematology1978;7(1):3‐18. [PUBMED: 657601] ">Stockman 1978</a>). This process is called physiologic anaemia of infancy (<a href="./references#CD004868-bbs2-0074" title="StraussRG . Current issues in neonatal transfusions. Vox Sanguinis1986;51(1):1‐9. [PUBMED: 3526725] ">Strauss 1986</a>). In very low birth weight (VLBW) infants, the haematocrit (the ratio of the volume of red blood cells to the total volume of blood) falls to approximately 24% in infants weighing 1.0 to 1.5 kg and to 21% in infants weighing less than 1.0 kg at birth (<a href="./references#CD004868-bbs2-0073" title="StockmanJA3rd . Anemia of prematurity. Current concept in the issue of when to transfuse. Pediatric Clinics of North America1986;33(1):111‐28. [PUBMED: 3513096] ">Stockman 1986</a>). In extremely low birth weight (ELBW) infants, this decline in haematocrit is not 'physiologic', as it may be associated with clinical findings that prompt red blood cell transfusions. To our knowledge, the diagnostic accuracy of different clinical signs and laboratory findings has not been studied (<a href="./references#CD004868-bbs2-0050" title="CohenA , MannoC . Transfusion practices in infants receiving assisted ventilation. Clinics in Perinatology1998;25(1):97‐111. [PUBMED: 9523077] ">Cohen 1998</a>). It is still unknown how low haematocrit levels can fall before clinical signs of anaemia occur and what the minimum haematocrit level is acceptable in infants requiring supplemental oxygen (<a href="./references#CD004868-bbs2-0066" title="OhlsRK . Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out. Journal of Pediatrics2002;141(1):3‐6. ">Ohls 2002</a>). Nevertheless, 'top‐up' transfusions to treat low haemoglobin or low haematocrit levels are frequently used. As many as 80% of VLBW infants and 95% of ELBW infants receive blood transfusions during their hospitalisations (<a href="./references#CD004868-bbs2-0076" title="WidnessJA , SewardVJ , KromerIJ , BurmeiserLF , BellEF , StraussRG . Changing patterns of red blood cell transfusion in very low birth weight infants. Journal of Pediatrics1996;129(5):680‐7. [PUBMED: 8917234] ">Widness 1996</a>). </p> </section> <section id="CD004868-sec-0018"> <h3 class="title" id="CD004868-sec-0018">Description of the intervention</h3> <p>Erythropoiesis‐stimulating agents (ESAs) currently include erythropoietin (EPO) and darbepoetin (Darbe). Plasma erythropoietin levels in neonates are lower than those of older children and adults. <a href="./references#CD004868-bbs2-0049" title="BrownMS , PhibbsRH , GraciaJF , DallmanPR . Postnatal changes in erythropoietin levels in untransfused premature infants. Journal of Pediatrics1983;103(4):612‐7. [PUBMED: 6194281] ">Brown 1983</a> reported that, between two and 30 days of life, the mean EPO concentration was 10 mU/mL, as compared to 15 mU/mL in concurrently studied adults. A low plasma EPO level is a key reason that nadir haematocrit values of preterm infants are lower than those of term infants (<a href="./references#CD004868-bbs2-0052" title="DallmanPR . Anemia of prematurity. Annual Review of Medicine1981;32:143‐60. [DOI: 10.1146/annurev.me.32.020181.001043; PUBMED: 7013658] ">Dallman 1981</a>; <a href="./references#CD004868-bbs2-0073" title="StockmanJA3rd . Anemia of prematurity. Current concept in the issue of when to transfuse. Pediatric Clinics of North America1986;33(1):111‐28. [PUBMED: 3513096] ">Stockman 1986</a>). Low plasma EPO levels provide a rationale for the use of EPO in the prevention or treatment of anaemia of prematurity. Studies in newborn monkeys and sheep have demonstrated that neonates have a larger volume of distribution and more rapid elimination of EPO, necessitating the use of higher doses than are required for adults (<a href="./references#CD004868-bbs2-0065" title="OhlsRK . The use of erythropoietin in neonates. Clinics in Perinatology2000;27(3):681‐96. [PUBMED: 10986635] ">Ohls 2000</a>). A systematic review of EPO administration noted a wide range of doses used, from 90 to 1400 IU/kg/week (<a href="./references#CD004868-bbs2-0063" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). Side effects reported in adults include hypertension, bone pain, rash, and rarely, seizures. Only transient neutropenia (low concentration of neutrophils, a type of white blood cell) has been reported in neonates (<a href="./references#CD004868-bbs2-0065" title="OhlsRK . The use of erythropoietin in neonates. Clinics in Perinatology2000;27(3):681‐96. [PUBMED: 10986635] ">Ohls 2000</a>). </p> </section> <section id="CD004868-sec-0019"> <h3 class="title" id="CD004868-sec-0019">How the intervention might work</h3> <p>The primary goal of ESAs therapy is to reduce transfusions. Most transfusions are given during the first three to four weeks of life. The larger or stable preterm infants who respond best to EPO receive few transfusions. ELBW infants, who are sick and have the greatest need for red blood cell (RBC) transfusions shortly after birth, have not consistently responded to EPO. This suggests that EPO is a more effective erythropoietic stimulator in more mature neonates. ELBW neonates are more likely to need transfusions even if their erythropoiesis is stimulated (<a href="./references#CD004868-bbs2-0063" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). In addition, ELBW neonates have a smaller blood volume and the relatively larger phlebotomy (phlebotomy ‐ the drawing of blood) volumes that are required during hospital stay often necessitate 'early' transfusions. In contrast, 'late' transfusions are more often given because of anaemia of prematurity (<a href="./references#CD004868-bbs2-0056" title='GarciaMG , HutsonAD , ChrisensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a>). Most preterm infants who require blood transfusions will receive their first transfusion in the first two weeks of life (<a href="./references#CD004868-bbs2-0078" title="ZipurskyA . Erythropoietin therapy for premature infants: cost without benefit?. Pediatric Research2000;48(2):136. [DOI: 10.1203/00006450‐200008000‐00002; PUBMED: 10926284] ">Zipursky 2000</a>). Reducing the number of RBC transfusions reduces the risk of transmission of viral infections and may reduce costs. Frequent RBC transfusions may be associated with retinopathy of prematurity (ROP) (abnormal blood vessel development in the retina of the eye) (<a href="./references#CD004868-bbs2-0058" title="HesseL , EberlW , SchlaudM , PoetsCF . Blood transfusion. Iron load and retinopathy of prematurity. European Journal of Pediatrics1997;156(6):465‐70. [PUBMED: 9208245] ">Hesse 1997</a>) and bronchopulmonary dysplasia (a chronic lung disease that affects newborns and infants) (BPD). </p> <p>In preterm infants, iron is needed for erythropoiesis. As neonatal blood volume expands with rapid growth, infants produce large amounts of haemoglobin. Several studies have observed a decrease in serum ferritin concentration (an indication of iron deficiency (<a href="./references#CD004868-bbs2-0055" title="FinchCA . Erythropoiesis, erythropoietin and iron. Blood1982;60:1241‐6. ">Finch 1982</a>) during erythropoietin treatment). The use of higher, more effective doses of erythropoietin might be expected to increase iron demand and the risk of iron deficiency. Iron supplementation during erythropoietin treatment has been observed to reduce the risk of the development of iron deficiency (<a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>). The range of iron doses used in EPO‐treated infants is between 1 mg/kg/day to 10 mg/kg/day (<a href="./references#CD004868-bbs2-0063" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). </p> <p>EPO has been found to have important non‐haematopoietic (formation of blood cellular components) functions in the brain and other organs during development (<a href="./references#CD004868-bbs2-0062" title="JuulS . Erythropoietin in the central nervous system, and its use to prevent hypoxic‐ischemic brain damage. Acta Paediatrica2002;91 Suppl(438):36‐42. [PUBMED: 12477263] ">Juul 2002</a>). Administration of EPO could potentially have a neuro‐protective effect in preterm infants, especially in perinatal asphyxia (<a href="./references#CD004868-bbs2-0053" title="DameC , JuulSE , ChristensenRD . The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biology of the Neonate2001;79(3‐4):228‐35. [DOI: 10.1159/000047097; PUBMED: 11275657] ">Dame 2001</a>; <a href="./references#CD004868-bbs2-0062" title="JuulS . Erythropoietin in the central nervous system, and its use to prevent hypoxic‐ischemic brain damage. Acta Paediatrica2002;91 Suppl(438):36‐42. [PUBMED: 12477263] ">Juul 2002</a>). This aspect of EPO use in neonates will be systematically reviewed separately (<a href="./references#CD004868-bbs2-0077" title="YuZ , GuoX , HanS , LuJ , SunQ , OhlssonA . Erythropoietin for term and late preterm infants with hypoxic ischemic encephalopathy. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD008316] ">Yu 2010</a>). </p> <p>A slightly modified, long‐acting version of EPO, darbepoetin alfa (Darbe), has been introduced (<a href="./references#CD004868-bbs2-0054" title="EgrieJC , BrowneJK . Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer2001;84 Suppl 1:3‐10. [DOI: 10.1054/bjoc.2001.1746; PUBMED: 11308268] ">Egrie 2001</a>). Darbepoetin was created by modifying five amino acids of the original EPO protein to generate two additional carbohydrate‐binding sites, thereby significantly increasing circulating half‐life and effectiveness. Compared with EPO, darbepoetin has an approximately three‐fold longer serum half‐life and greater in vivo potency. It can be administered less frequently to obtain the same biological response. A single subcutaneous dose of Darbe has been shown to accelerate erythropoiesis in preterm infants (<a href="./references#CD004868-bbs2-0045" title="WarwoodTL , OhlsRK , WiedmeierSE , LambertDK , JonesC , ScoffieldSH , et al. Single‐dose darbepoetin administration to anemic preterm neonates. Journal of Perinatology2005;25(11):725‐30. [DOI: 10.1038/sj.jp.7211387; PUBMED: 16151471] ">Warwood 2005</a>). </p> <p>It is likely that additional studies of ESAs in preterm or LBW infants have been published since the reviews noted above, which included reports up to October 2002. We have performed a series of Cochrane reviews on the use of EPO in preterm infants, including: <i>Early erythropoiesis‐stimulating agents in preterm or low birth weight infants (</i><a href="./references#CD004868-bbs2-0068" title="OhlssonA , AherSM . Early erythropoiesis‐stimulating agents in preterm or low birth weight infants. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD004863.pub5] ">Ohlsson 2017</a>), this review (late erythropoietin; <a href="./references#CD004868-bbs2-0080" title="AherSM , OhlssonA . Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD004868.pub3] ">Aher 2012a</a>; <a href="./references#CD004868-bbs2-0081" title="AherSM , OhlssonA . Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD004868.pub4] ">Aher 2014</a>), and <i>Early versus late erythropoietin to prevent red blood cell transfusion in preterm and/or low birth weight infants</i> (<a href="./references#CD004868-bbs2-0048" title="AherSM , OhlssonA . Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD004865.pub3] ">Aher 2012b</a>). The cut‐off of seven days of age or less for 'early' and more than seven days for 'late' treatment with EPO, although somewhat arbitrary, was chosen based on previously published meta‐analyses (<a href="./references#CD004868-bbs2-0056" title='GarciaMG , HutsonAD , ChrisensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a>; <a href="./references#CD004868-bbs2-0063" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>), and allowed us to compare the results between our reviews and previously published reviews. It is of note that in the latest update of the <i>Early erythropoiesis‐stimulating agents in preterm or low birth weight infants (</i><a href="./references#CD004868-bbs2-0068" title="OhlssonA , AherSM . Early erythropoiesis‐stimulating agents in preterm or low birth weight infants. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD004863.pub5] ">Ohlsson 2017</a>) review, there was no significant difference in the incidence of ROP with the treatment with ESAs compared to controls. </p> </section> <section id="CD004868-sec-0020"> <h3 class="title" id="CD004868-sec-0020">Why it is important to do this review</h3> <p>This review concerns late administration of ESAs (starting in infants between eight and 28 days of age, after reaching 40 weeks' postmenstrual age (PMA)). The main rationale for such EPO therapy is to avoid exposure of neonates to multiple blood donors and the risks associated with this exposure. It is likely that many sick neonates would have received a transfusion prior to entry into trials enrolling infants more than seven days of age. We carried out a systematic review to evaluate all available studies where ESAs were begun after seven days of life, to assess the effect on the use of one or more red blood cell transfusions in preterm or very low birth weight infants. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004868-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004868-sec-0021"></div> <section id="CD004868-sec-0022"> <h3 class="title" id="CD004868-sec-0022">Primary objective</h3> <p>To assess the effectiveness and safety of late initiation of ESAs between eight and 28 days after birth in reducing red blood cell (RBC) transfusions in preterm or low birth weight infants. </p> </section> <section id="CD004868-sec-0023"> <h3 class="title" id="CD004868-sec-0023">Secondary objective</h3> <p>To distinguish between the effectiveness and safety of the intervention by subgroup analyses of low (≤ 500 IU/kg/week) and high (&gt; 500 IU/kg/week) doses of EPO, and low (≤ 5 mg/kg/day) and high (&gt; 5 mg/kg/day) doses of supplemental iron in reducing red blood cell transfusions in preterm or low birth weight infants. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004868-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004868-sec-0024">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004868-sec-0120">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004868-sec-0024"></div> <section id="CD004868-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004868-sec-0026"> <h4 class="title">Types of studies</h4> <p>Randomised or quasi‐randomised controlled trials.</p> </section> <section id="CD004868-sec-0027"> <h4 class="title">Types of participants</h4> <p>Preterm (&lt; 37 weeks) and/or low birth weight (&lt; 2500 grams) neonates between eight and 28 days of age. </p> </section> <section id="CD004868-sec-0028"> <h4 class="title">Types of interventions</h4> <p>Late initiation of ESAs, at eight to 28 days of age, using any dose, route, or duration of treatment, versus placebo or no intervention. The use of any dose of supplemental iron. </p> </section> <section id="CD004868-sec-0029"> <h4 class="title">Types of outcome measures</h4> <section id="CD004868-sec-0030"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004868-list-0001"> <li> <p>Use of one or more red blood cell transfusions.</p> </li> </ol> </p> </section> <section id="CD004868-sec-0031"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004868-list-0002"> <li> <p>The total volume (mL/kg) of blood transfused per infant.</p> </li> <li> <p>Number of transfusions per infant.</p> </li> <li> <p>Number of donors to whom the infant was exposed.</p> </li> <li> <p>Mortality during initial hospital stay (all causes of mortality).</p> </li> <li> <p>Retinopathy of prematurity (ROP) (any stage and stage ≥ 3).</p> </li> <li> <p>Proven sepsis (clinical symptoms and signs of sepsis and positive blood culture for bacteria or fungi). </p> </li> <li> <p>Necrotising enterocolitis (NEC) (Bell's stage II or more).</p> </li> <li> <p>Intraventricular haemorrhage (IVH); all grades and grades III and IV.</p> </li> <li> <p>Periventricular leukomalacia (PVL); cystic changes in the periventricular areas.</p> </li> <li> <p>Bronchopulmonary dysplasia (BPD) (supplementary oxygen at 28 days of age or at 36 weeks' postmenstrual age (PMA) and compatible X‐ray). </p> </li> <li> <p>Sudden infant death after discharge.</p> </li> <li> <p>Long‐term outcomes assessed at any age beyond one year of age by a validated cognitive, motor, language, or behavioural/school/social interaction/adaptation test. </p> </li> <li> <p>Neutropenia.</p> </li> <li> <p>Hypertension (as this outcome was frequently reported by trial authors, it has been added since the protocol was published). </p> </li> <li> <p>Length of hospital stay (days).</p> </li> <li> <p>Any side effects reported in the trials.</p> </li> </ol> </p> </section> </section> </section> <section id="CD004868-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see the Cochrane Neonatal <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">search strategy</a> for specialised register). We searched for errata or retractions from included studies published in full‐text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>) on June 5th, 2018. We did not limit the search to any geographical region, language, or timing of publication. </p> <section id="CD004868-sec-0033"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive search including: Cochrane Central Register of Controlled Trials (CENTRAL 2018, Issue 5) in the Cochrane Library; MEDLINE via PubMed (1966 to 5 June 2018); Embase (1980 to 5 June 2018); and CINAHL (1982 to 5 June 2018) using the following search terms: ("Erythropoietin"[Mesh] OR Erythropoietin OR "recombinant human erythropoietin" OR rhuepo OR rhepo OR darbepoetin), plus database‐specific limiters for RCTs and neonates (see <a href="./appendices#CD004868-sec-0101">Appendix 1</a> for the full search strategies for each database; see <a href="./appendices#CD004868-sec-0102">Appendix 2</a> for the search methods for previous versions of this review). We did not apply language restrictions. </p> <p>We searched, on August 27th 2018, clinical trials registries for ongoing or recently completed trials (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; the World Health Organization’s International <a href="http://apps.who.int/trialsearch/default.aspx" target="_blank">Trials Registry</a> and Platform, and the ISRCTN <a href="http://www.isrctn.com/" target="_blank">Registry</a>). </p> </section> <section id="CD004868-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We also searched the reference lists of any articles selected for inclusion in this review in order to identify additional relevant articles. </p> </section> </section> <section id="CD004868-sec-0035"> <h3 class="title" id="CD004868-sec-0035">Data collection and analysis</h3> <p>We used the standard methods of the Cochrane Neonatal Review Group and the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004868-bbs2-0060" title="HigginsJP , GreenS editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) for data collection and analysis. </p> <section id="CD004868-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AO, SA) assessed all abstracts and published studies identified as potentially relevant by the literature search for inclusion in the review. Each review author extracted data separately onto a data abstraction form. They then compared the information and resolved differences by consensus. One review author (AO) entered the data into Review Manager 5 (<a href="./references#CD004868-bbs2-0069" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) and the other (SA) cross‐checked the printout against his own data abstraction forms and corrected errors. </p> <p>For studies identified as abstracts only, we planned to contact the primary author to obtain further information. The two studies identified as abstracts did not provide enough information for us to be able to contact the authors (<a href="./references#CD004868-bbs2-0033" title="Ahmadpour KachoM , Zahed PashaYA , EsmailiMR , HajianK , MoradiSH . The effect of human recombinant erythropoietin on prevention of anemia of prematurity. Pediatric Research2003;54(4):564. ">Ahmadpour Kacho 2004</a>; <a href="./references#CD004868-bbs2-0034" title="AminAA , AlzahraniDM . Efficacy of erythropoietin in premature infants. Pediatric Research2003;54(4):557. [PUBMED: 11938417] ">Amin 2004</a>). </p> <p>This update, in 2018, was conducted by both review authors (SA and AO).</p> </section> <section id="CD004868-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>The review authors separately extracted, assessed, and coded all data for each study using a form that was designed specifically for this review. We replaced any standard error of the mean by the corresponding standard deviation. </p> </section> <section id="CD004868-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AO, SA) independently assessed the risk of bias (low, high, or unclear) of all included trials using the Cochrane ‘Risk of bias’ tool (<a href="./references#CD004868-bbs2-0061" title="HigginsJP , GreenS editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook. ">Higgins 2017</a>) for the following domains: </p> <p> <ul id="CD004868-list-0003"> <li> <p>Sequence generation (selection bias);</p> </li> <li> <p>Allocation concealment (selection bias);</p> </li> <li> <p>Blinding of participants and personnel (performance bias);</p> </li> <li> <p>Blinding of outcome assessment (detection bias);</p> </li> <li> <p>Incomplete outcome data (attrition bias);</p> </li> <li> <p>Selective reporting (reporting bias);</p> </li> <li> <p>Any other bias.</p> </li> </ul> </p> <p>Any disagreements were resolved by discussion or by a third assessor if necessary. See <a href="./appendices#CD004868-sec-0103">Appendix 3</a> for a more detailed description of risk of bias for each domain.  </p> <p>For the original review, two review authors (SA, AO) who were not blinded to authors, institution or journal of publication, conducted independent quality assessments. </p> <p>The 2012 update was conducted by one author (AO) and the updates in 2014 and 2018 by both authors (SA and AO). </p> </section> <section id="CD004868-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>The statistical methods include (typical, when applicable) risk ratio (RR), risk difference (RD), number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat to treat for an additional harmful outcome (NNTH) for dichotomous outcomes, and mean difference (MD) for continuous outcomes, all reported with their 95% confidence intervals (CIs). </p> </section> <section id="CD004868-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>In all studies, the individual infant was the unit of analysis.</p> </section> <section id="CD004868-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>We approached trial authors for additional data or for clarification of data.</p> </section> <section id="CD004868-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>We conducted heterogeneity tests including the I² statistic to assess the appropriateness of pooling the data (<a href="./references#CD004868-bbs2-0059" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557; PUBMED: 12958120] ">Higgins 2003</a>). In this update of the review we used the following categories for heterogeneity: less than 25% no heterogeneity; 25% to 49% low heterogeneity; 50% to 74% moderate heterogeneity and 75% or greater high heterogeneity. </p> </section> <section id="CD004868-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>We prepared a funnel for the primary outcome in Comparison 1 ‐ use of one or more red blood cell transfusions (low and high dose of EPO). </p> </section> <section id="CD004868-sec-0044"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analysis using Review Manager 5 software (<a href="./references#CD004868-bbs2-0069" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), supplied by Cochrane. For estimates of typical RR and RD, we used the Mantel‐Haenszel method. For measured quantities, we used the inverse variance method. All meta‐analyses were done using the fixed‐effect model. We considered a P value of &lt; 0.05 as statistically significant. </p> <section id="CD004868-sec-0045"> <h5 class="title">Quality of evidence</h5> <p> <ul id="CD004868-list-0004"> <li> <p>We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, as outlined in the <a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">GRADE Handbook</a> (<a href="./references#CD004868-bbs2-0071" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed prior to 23 January 2019). ">Schünemann 2013</a>), to assess the quality of evidence for the following (clinically relevant) outcomes in infants exposed to late EPO versus placebo or sham injection. To make the outcomes of this review comparable to the "Early erythropoiesis‐stimulating agents in preterm or low birth weight infants review" (<a href="./references#CD004868-bbs2-0068" title="OhlssonA , AherSM . Early erythropoiesis‐stimulating agents in preterm or low birth weight infants. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD004863.pub5] ">Ohlsson 2017</a>), we chose to use the same primary outcome and the same secondary outcomes, when available, and in which two or more studies were included in the analyses for this review. For this review, no long‐term outcomes were reported. No studies using Darbe were identified. </p> </li> </ul> </p> <p>Primary outcomes:</p> <p> <ul id="CD004868-list-0005"> <li> <p>Use of one or more red blood cell transfusions (low and high doses of EPO).</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD004868-list-0006"> <li> <p>NEC ( ≥ Bell's stage 2);</p> </li> <li> <p>Mortality during initial hospital stay (all causes of mortality);</p> </li> <li> <p>Retinopathy of prematurity (ROP) (any stage);</p> </li> <li> <p>Retinopathy of prematurity (ROP) (stage ≥ 3).</p> </li> </ul> </p> <p>IVH is probably not a relevant outcome in this review as most haemorrhages occur during the first few days of life and infants were enrolled later in these studies. We did not include this outcome in the 'Summary of findings' table. </p> <p>In this review, no long‐term follow‐up results were reported.</p> <p>Two authors (AO, SA) independently assessed the quality of the evidence for each of the outcomes above. We considered evidence from randomised controlled trials as high quality but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used the <a href="./references#CD004868-bbs2-0057" title="GRADE Working Group, McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 5 June 2018. Hamilton (ON): GRADE Working Group, McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a> Guideline Development Tool to create a ‘Summary of findings’ table to report the quality of the evidence. </p> <p>The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades: </p> <p> <ol id="CD004868-list-0007"> <li> <p>High: We are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> </section> </section> <section id="CD004868-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses for low (≤ 500 IU/kg/week) and high (&gt; 500 IU/kg/week) doses of EPO, and in addition within those subgroups for no iron, low (≤ 5 mg/kg/day) and high (&gt; 5 mg/kg/day) doses of supplemental iron (co‐intervention). </p> </section> <section id="CD004868-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>In an attempt to further explore the heterogeneity observed in the primary outcome and subgroup analyses, we performed a post hoc analysis comparing the results of studies that we judged as high quality with those that we identified as of lower quality or could not precisely define their quality because of lack of information. We compared the results of studies that used well defined criteria for red blood cell transfusions to those that used no criteria or less well defined criteria. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004868-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004868-sec-0048"></div> <section id="CD004868-sec-0049"> <h3 class="title">Description of studies</h3> <p>For the previous feedback‐initiated update, the study by Romagnoli (<a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a>) was moved from the early EPO review (<a href="./references#CD004868-bbs2-0067" title="OhlssonA , AherSM . Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD004863.pub3] ">Ohlsson 2012</a>) to this late EPO review as the infants were of a mean (SD) age of 10 (±1) days at the initiation of EPO treatment. The study enrolled 230 infants. The 2012 update identified one new study for inclusion as did this update in 2018. As a result, 31 studies (32 comparisons) including 1651 preterm or low birth weight infants met the inclusion criteria. These studies were performed in 22 countries (Argentina, Australia, Austria, Belgium, Brazil, Canada, Finland, France, Germany, Greece, Iran, Israel, Italy, Japan, Norway, South Africa, Spain, Switzerland, Taiwan (Republic of China), the UK, Turkey, the USA). We decided to include studies that enrolled some infants who were less than eight days at study entry if most of the infants enrolled were older at entry. We made one further deviation from our protocol, as we included studies that enrolled infants beyond 28 days of age. Most of these studies enrolled some infants who were less than 28 days old but the inclusion criteria did not have 28 days of postnatal age as an upper limit. We could not separate out data for infants that were under 28 days at enrolment. The inclusion of these studies makes our review more comprehensive. The age at enrolment is stated for each study in the table <a href="./references#CD004868-sec-0118" title="">Characteristics of included studies</a>. </p> <section id="CD004868-sec-0050"> <h4 class="title">Results of the search</h4> <p>The study flow diagram shows the results of the searches (<a href="#CD004868-fig-0001">Figure 1</a>). Only one new study (<a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a>) was identified for this update. No new ongoing trial was identified. No study investigated Darbe. </p> <div class="figure" id="CD004868-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update" data-id="CD004868-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> </div> </section> <section id="CD004868-sec-0051"> <h4 class="title">Included studies</h4> <p>We included 31 studies (32 comparisons) in this review. We treated the report by Giannakopoulou as two separate studies; under <a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a>, we reported on the 32 infants weighing &lt; 1000 grams and under <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a>, we reported on the 36 infants weighing 1000 to 1300 grams. The studies are detailed in the table <a href="./references#CD004868-sec-0118" title="">Characteristics of included studies</a> and are briefly discussed below. </p> <p>The detailed guidelines, used for transfusions, are outlined in the Additional Table (<a href="#CD004868-tbl-0002">Table 1</a>: <i>Transfusion Guidelines</i>). </p> <div class="table" id="CD004868-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Transfusion guidelines</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0001" title="AkisuM , TuzunS , ArslanogluS , YalazM , KultursayN . Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Medica Okayama2001;55(6):357‐62. [DOI: 10.18926/AMO/31997; PUBMED: 11779098] ">Akisu 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guidelines for transfusions were not presented.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0002" title="Al‐KharfyT , SmythJA , WadsworthL , KrystalG , FitzgeraldC , DavisJ , et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics1996;129(1):89‐96. [PUBMED: 8757567] SmythJA , AinsworthL , KrystalG , WadsworthL . Effect of erythropoietin therapy on oxygen dependency in premature infants. Pediatric Research2002;51(3):330 A. ">Al‐Kharfy 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The indications for transfusion were 1) shock, 2) cumulative loss of ≥ 10% of the blood volume in 72 hours or less when further blood sampling is expected, 3) Hb &lt; 130 g/L in acutely ill neonates with cardiorespiratory disease, and 4) Hb &lt; 80 to 100 g/L with clinical signs of anaemia. A volume of 15 mL/kg was recommended for each transfusion. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0003" title="AtasayB , GunlemezA , AkarN , ArsanS . Does early erythropoietin therapy decrease transfusions in anemia of prematurity?. Indian Journal of Pediatrics2002;69(5):389‐91. [PUBMED: 12061670] ">Atasay 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criteria for blood transfusion (10 mL/kg packed red cells) were as follows: a Hct &lt; 30% when signs and symptoms attributed to anaemia including persistent tachycardia (180 beats/min for 24 hours), frequent apnoea with bradycardia and daily weight gain &lt; 10 g/kg despite optimal protein and caloric intake (3.5 g/kg, 100 kcal/kg/day). Infants were transfused with a Hct of 35% to 40% if they received more than 40% oxygen or ventilation therapy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0004" title="BaderD , BlondheimO , JonasR , AdmoniO , Abend‐WingeM , ReichD , et al. Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity. Acta Paediatrica1996;85(4):496‐501. [PUBMED: 8740313] ">Bader 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criteria for blood transfusion (10 mL/kg of red cells) were as follows: a) a Hct &lt; 25%, b) an increased frequency of apnoeic events which required either stimulation or aminophylline therapy, c) changes in heart rate patterns, e.g. an increase in frequency of bradycardia (&lt; 80 beats/min) or tachycardia (&gt; 180 beats/min, d) failure of weight gain of &gt; 10 g/kg/day despite an optimal caloric intake of &gt; 120 kcal/day and e) lethargy without evidence of sepsis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines for preterm infants included: (1) asymptomatic infants with Hct &lt; 21% and reticulocytes &lt; 2%; (2) infants with haematocrit &lt; 31% and hood O<sub>2</sub> &lt; 36% or mean airway pressure &lt; 6 cm H<sub>2</sub>O by continuous positive airway pressure (CPAP) or intermittent mandatory ventilation (IMV) or &gt; 9 apnoeic and bradycardic episodes per 12 hours or 2/24 hours requiring bag‑and‑mask ventilation while on adequate methylxanthine therapy or heart rate &gt; 18/min or respiratory rate &gt; 80/min sustained for 24 hours or weight gain of &lt; 10 g/day for 4 days on 100 kcal/kg/day or having surgery; (3) infants with haematocrit &lt; 36% and requiring &gt; 35% O<sub>2</sub> or mean airway pressure of 6 to 8 cm H<sub>2</sub>O by CPAP or IMV. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0006" title="BechensteenAG , HagaP , HalvorsenS , WhitelawA , LiestolK , LindemannR , et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Archieves of Disease in Childhood1993;69(1 Spec No):19‐23. [PUBMED: 8346946] BechensteenAG , HalvorsenS , HagaP . Erythropoiesis during rapid growth. Role of erythropoietin and nutrition. Annals of the New York Academy of Sciences1994;718:339‐40. [PUBMED: 8185241] BechensteenAG , HalvorsenS , HagaP , CotesPM , LiestolK . Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatrica1996;85(4):490‐5. [PUBMED: 8346946] BechensteenAG , RefsumHE , HalvorsenS , HagaP , LiestolK . Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants. Pediatric Research1995;38(5):729‐32. [DOI: 10.1203/00006450‐199511000‐00016; PUBMED: 8552441] ">Bechensteen 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indications of blood transfusions were: 1) Hb &lt; 80 g/L or 2) otherwise at the discretion of the clinician caring for the infant according to symptoms and signs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very specific transfusion criteria were in place for infants on mechanical ventilation, for infants who required supplemental oxygen and for infants on room air. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were given because of frequent and prolonged apnoea.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were considered based on the clinical condition (pallor, tachycardia, tachypnoea, apnoea with or without bradycardia, poor weight gain, difficulties with sucking) and haematological parameters (Hb &lt; 70 g/L, Hct &lt; 26%, with low reticulocyte counts). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0010" title="DonatoH , RendoP , VivasR , SchvartzmanG , DigregorioJ , VainN . Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double‐blind, placebo‐controlled trial comparing three different doses. International Journal of Pediatric Hematology/Oncology1996;3:279‐85. ">Donato 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During the first week of life, infants were given transfusions of packed red blood cells for replacement when blood drawn for analysis was in excess of 8 mL/kg of body weight; fresh whole blood was given if signs attributable to hypovolaemia or anaemia developed. Subsequently, infants with heart rate &gt; 180 beats/min, severe apnoea/bradycardia or poor weight gain (&lt; 10 grams/day in spite of a 100 calories/day intake during 5 consecutive days) were transfused if the Hct was &lt; 25% (or &lt; 30% if oxygen or mechanical ventilation was required); asymptomatic infants were transfused only when a central Hct &lt; 23% was reached. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0011" title="EmmersonAJ , ColesHJ , SternCM , PearsonTC . Double blind trial of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood1993;68(3 Spec No):291‐6. [PUBMED: 8466265] ">Emmerson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The decision to give a blood transfusion to a study infant was made by the medical staff of the neonatal unit who were blinded to the randomisation. The unit policy at the time of the study was to transfuse a preterm infant who had a Hb &lt; 100 g/L and who had symptoms consistent with those caused by anaemia. The symptoms and signs of anaemia included poor feeding, tachycardia, tachypnoea, apnoea, and pallor. Infants with a Hb &lt; 80 g/L were transfused even if asymptomatic. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a>; <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indications for blood transfusion were a Hb &lt; 80 g/L or otherwise at the discretion of the physician treating the infants according to symptoms and signs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants were transfused if they were ventilated and/or oxygen‐dependent with a Hb of &lt; 120 g/L, had clinically symptomatic anaemia, or were asymptomatic with a Hb of &lt; 70 g/L. Infants were transfused if they were ventilated and/or oxygen‐dependent with a Hb of &lt; 120 g/L, had clinically symptomatic anaemia, or were asymptomatic with a haemoglobin of &lt; 70 g/L. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0015" title="Javier ManchonG , Natal PujolA , Coroleu LletgetW , Zuasnabar CotroA , Badia BarnusellJ , Junca PieraJ , et al. Randomized multi‐centre trial of the administration of erythropoietin in anemia of prematurity [Estudio multicentrico aleatorizado de administracion de eritropoyetina en la anemia de la prematuridad]. Anales Espanoles de Pediatria1997;46(6):587‐92. [PUBMED: 9297428] ">Javier Manchon 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines were similar in all three centres (details not provided).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>By NICU policy, on admission, infants weighing &lt; 1000 grams at birth were assigned 1 unit of packed red blood cells divided into 8 aliquots. These aliquots were used for transfusions during the first month of life. The following transfusion guideline was used for infants of all birth weights: Transfusion is recommended for a Hct &lt; 35% if the infant requires positive pressure with a mean airway pressure &gt; 6 cm H<sub>2</sub>O and requires &gt; 35% oxygen. Transfusion is recommended for Hct &lt; 30% if the infant requires oxygen (&lt; 35% FIO<sub>2</sub>), is receiving continuous positive airway pressure or intubated with mean airway pressure &lt; 6 cm H<sub>2</sub>O, if an infant has significant apnoea and bradycardia while receiving methylxanthines (&gt; 9 episodes in 12 hours or 2 episodes in 24 hours requiring mask‐and‐bag ventilation), if the heart rate is &gt; 180 beats/min or respiratory rate &gt; 80/min and persists for 24 hours, if weight gain &lt; 10 grams/day over 4 days despite adequate calories, or in the presence of sepsis. If the Hct is &lt; 20%, no symptoms are necessary for transfusion.<br/> Transfusion volumes were standardised as follows: infants received an initial transfusion of 15 mL/kg over a period of 3 to 4 hours. A follow‐up Hct was checked after 4 hours. If the Hct was &lt; 30%, a second aliquot of 10 mL/kg was given </p> <p>If the Hct was between 30% and 35%, an additional 5 mL/kg was given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0017" title="KivivuoriSM , VirtanenM , RaivioKO , ViinikkaL , SiimesMA . Oral iron is sufficient for erythropoietin treatment of very low birth‐weight infants. European Journal of Pediatrics1999;158(2):147‐51. [PUBMED: 10048613] ">Kivivuori 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The Hct values were maintained at &gt; 30% by red blood cell transfusions (10 mL/kg per time) in asymptomatic infants. In infants who had symptoms or signs of anaemia, red blood cells were transfused if the Hct value was &lt; 40%. The transfusion policies were the same in all study hospitals. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0018" title="KumarP , ShankaranS , KrishnanRG . Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double‐blind, placebo‐controlled trial. Journal of Perinatology1998;18(3):173‐7. [PUBMED: 9659643] ">Kumar 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The need for erythrocyte transfusion was assessed by the clinicians caring for each infant and the decision to transfuse was made without consulting the study investigators. According to the practice in the NICU, infants received transfusion if a Hct level of &lt; 27% was associated with one of the following signs and symptoms of anaemia: 1) frequent apnoea and bradycardia, defined as &gt; 6 episodes in 12 hours or any episode requiring bag‐and‐mask ventilation, in an infant with therapeutic serum levels of theophylline; 2) persistent tachycardia, defined as &gt; 180 beats/min for more than 12 hours; 3) poor weight gain (&lt; 10 grams/day averaged over a 7‐day period) despite adequate caloric intake; and 4) increasing oxygen requirement in infants with chronic lung disease despite optimum diuretic and bronchodilator therapy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0019" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [PUBMED: 12091844] ">Maier 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants with artificial ventilation or in &gt; 40% of inspired oxygen were not transfused unless Hct dropped to &lt; 40%. Spontaneously breathing infants were not transfused unless Hct dropped to &lt; 35% during the first 2 weeks of life, 30% during the 3rd to 4th weeks, and 25% thereafter. Transfusion was allowed when life‐threatening anaemia or hypovolaemia was assumed by the treating neonatologist, or surgery was planned. Twelve of the 14 centres used satellite packs of the original red cell pack to reduce donor exposure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0020" title="MeyerMP , HaworthC , McNeillL . Is the use of recombinant human erythropoietin in anemia of prematurity cost‐effective?. South African Medical Journal1996;86(3):251‐3. [PUBMED: 8658295] MeyerMP , MeyerJH , CommerfordA , HannFM , SiveAA , MollerG , et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double‐blind, placebo‐controlled study. Pediatrics1994;93(6 Pt 1):918‐23. [PUBMED: 8190577] ">Meyer 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct quote: "The need for blood transfusion was assessed by the attending neonatal physician and decisions were made independently of the investigators. The following guidelines were developed, based on existing literature and nursery practices: </p> <p><b>a</b>. Hct &lt; 30% and </p> <p>1) Weight gain of &lt; 10 grams/day averaged over 1‐week period (infant tolerating full oral feeds and receiving adequate calories). </p> <p>2) Three or more episodes of apnoea (respirations absent for 20 seconds) or bradycardia (heart rate of &lt; 100 beats per minute) in a 24‐hour period not due to other causes and not responsive to methylxanthine treatment. </p> <p>3) Tachycardia (&gt; 170 beats/min) or tachypnoea (&gt; 70 breaths/min) sustained over a 24‐hour period or associated with acute cardiac decompression. </p> <p>4) A requirement for surgery.</p> <p><b>b</b>. Development of a clinically significant patent ductus arteriosus (i.e. at least three of the following features: heart rate &gt; 160 beats/min, brisk brachial and/or dorsalis pedis pulses, palpable precordial pulsation, systolic murmur, cardiomegaly on chest radiograph). </p> <p><b>c</b>. Pulmonary disease and fractional inspired oxygen concentrations increasing by &gt; 10% per week. </p> <p><b>d</b>. Systemic infection (either clinically suspected or proven on blood culture) associated with a sudden decrease in hematocrit. </p> <p><b>e</b>. Hematocrit of 22% or less and an absolute reticulocyte count of &lt; 100 000 x 10<sup>9</sup>/L". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0021" title="KasperDC , WidnessJA , HaidenN , Berger A. HaydeM , PollakA , et al. Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram. Neonatology2009;95(2):164‐71. [PUBMED: 18776731] PollakA , HaydeM , HaynM , HerknerK , LombardKA , LubecG , et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin‐treated premature infants. Pediatrics2001;107(1):78‐85. [PUBMED: 11134438] ">Pollak 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard NICU transfusion criteria were used (authors refer to <a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>; see below). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0022" title="ReiterPD , RosenbergAA , ValuckR , NovakK . Effect of short‐term erythropoietin therapy in anemic premature infants. Journal of Perinatology2005;25(2):125‐9. [PUBMED: 15526012] ">Reiter 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conservative transfusion guidelines were in place and followed. Criteria for red blood cell transfusion in the acutely ill infant requiring mechanical ventilation or nasal continuous positive airway pressure included: phlebotomy loss of &gt; 15% of blood volume associated with hypotension, or Hct &lt; 30%. Criteria for red blood cell transfusion in the convalescent infant requiring no more than supplemental oxygen included: Hct &lt; 28% with symptomatic anaemia (tachycardia, poor somatic growth, or metabolic acidosis) or Hct &lt; 20%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0023" title="RochaVL , BenjaminAC , ProcianoyRS . The effect of recombinant human erythropoietin on the treatment of anemia of prematurity. Journal de Pediatria2001;77(2):75‐83. [PUBMED: 14647595] ">Rocha 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The decision for blood transfusion within the whole study population was made by the assistant doctor of each newborn, and was based on the following criteria: Hct ≤ 20%, inadequate weight gain, 3 or more apnoea or bradycardia episodes within 24 hours, presurgical procedure requirement, disease associated with sudden Hct decline, restoration of the blood collected for lab exams, maintenance of Hct up to 30% associated with minimal ventilatory support requirement, and Hct up to 35% when ventilation requirements are greater. The assistant doctor who recommended blood transfusion did not know to which group the infant belonged. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants on mechanical ventilation and/or on more than 30% of inspired oxygen received packed erythrocytes when their Hct levels dropped below 40%. Otherwise the transfusion was performed when the Hct fell below 35% from the 2nd to the 4th week of life and below 23% thereafter. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0025" title="RonnestadA , MoePJ , BreivikN . Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anaemia of prematurity. Acta Paediatrica1995;84(7):809‐11. [PUBMED: 7549303] ">Ronnestad 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were given on the orders of the attending physician if Hb was &lt; 90 g/L or otherwise as necessary according to signs and symptoms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The need for packed erythrocyte transfusions was judged by the attending neonatologist. Guidelines for erythrocyte transfusions were developed as follows: 1) Hct of ≤ 22% and an absolute reticulocyte count of 100 000/microlitre; 2) Hct of ≤ 30% and a) tachycardia (&gt; 180 beats/min) and tachypnoea (&gt; 70 breaths/min) persisting for 24 hours; or b) 3 or more episodes of apnoea or bradycardia in 24 hours, not due to other causes and not responsive to methylxanthine treatment; or c) average weight gain of &lt; 10 grams/day over a 1‐week period (infant tolerating full oral feed and receiving adequate calories); or d) undergoing surgery; 3) systemic infection associated with a sudden decrease in Hct. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were ordered by the clinicians caring for each infant without consulting the investigators. Written guidelines for erythrocyte transfusions were developed for the nursery 1 year before the start of the study. A copy of these guidelines was taped to the bed of each study infant. In general, babies who were otherwise well received transfusions only if they had a Hct &lt; 25% and signs referable to their anaemia, such as slowing in rate of growth, persistent severe tachycardia and tachypnoea, or worsening of episodes of apnoea and bradycardia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0028" title="ShannonKM , MentzerWC , AbelsRI , WertzM , Thayer‐MoriyamaJ , LiWY , et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. Journal of Pediatrics1992;120(4 Pt 1):586‐92. ">Shannon 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See <a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a> above. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfuse infants at Hct ≤ 20%: a) if asymptomatic with reticulocytes &lt; 100 000/microlitre.</p> <p>Transfuse infants at Hct ≤ 30%: a) if receiving &lt; 35% supplemental hood oxygen, b) if on CPAP or mechanical ventilation with mean airway pressure &lt; 6 cm H<sub>2</sub>O, c) if significant apnoea and bradycardia are noted (9 episodes in 12 hours or 2 episodes in 24 hours requiring bag‐and‐mask ventilation) while receiving therapeutic doses of methylxanthines, d) if heart rate &gt; 180 beats/min or respiratory rate &gt; 80 breaths /min persists for 24 hours, e) if weight gain &lt; 10 grams/day is observed over 4 days while receiving ≥ 100 kcal/kg/day, f) if undergoing surgery. </p> <p>Transfuse for Hct ≤ 35%: a) if receiving &gt; 35% supplemental hood oxygen, b) if intubated on CPAP or mechanical ventilation with mean airway pressure ≥ 6 to 8 cm H<sub>2</sub>O. </p> <p>Do not transfuse: a) to replace blood removed for laboratory tests alone, b) for low Hct alone. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0030" title="WhitehallJS , PatoleSK , CampbellP . Recombinant human erythropoietin in anemia of prematurity. Indian Pediatrics1999;36(1):17‐27. [PUBMED: 10709119] ">Whitehall 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guidelines for red cell transfusions for anaemia of prematurity were based on the existing policy in the nursery, generally adopted by the neonatologists. They were as follows:<br/> I. Transfuse infants at Hb 80 g/L, (a) If reticulocyte count is &lt; 4% and (b) If receiving supplemental oxygen &gt; 30% or (c) If unexplained recurrent apnoea/bradycardia is noted (&gt; 1 to 2/hour) or (d) If persistent tachycardia (heart rate &gt; 170/min) or tachypnoea (respiratory rate &gt; 60/min) is noted, or (e) If there is failure to gain weight or successive weight loss on weekly recordings for 3 consecutive weeks. In absence of a clear evidence in the literature justifying red cell transfusions at a Hb of 80 g/L in otherwise asymptomatic neonates who are failing to thrive, it was decided that failure to gain weight or successive weight loss on weekly recordings for 3 consecutive weeks was a fair and substantial clinical indicator of the need to transfuse.<br/> II. Transfuse infants at Hb 100 g/L, (a) If receiving supplemental oxygen 30% and (b) needing intermittent mandatory ventilation or continuous positive airway pressure by nasal prongs for recurrent (&gt; 1 to 2 per hour), apnoea/bradycardia with saturations &lt; 90% on the pulse oximeter.<br/> III. Transfuse Infants at Hb 120 g/L, (a) If receiving mechanical ventilatory support with mean airway pressure 10 cm H<sub>2</sub>O and supplemental oxygen 30% during the acute phase of illness after birth. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0031" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm. Acta Neonatologica Japonica1999;35(4):755‐61. ">Yamada 1999a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conservative red blood cell transfusion guidelines were followed (details not presented, as we were unable to translate the information). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0032" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm. Acta Neonatologica Japonica1999;35(4):762‐7. ">Yamada 1999b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conservative red blood cell transfusion guidelines were followed (details not presented, as we were unable to translate the information). </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>CPAP: continuous positive airways pressure<br/> FIO2: fraction of inspired oxygen<br/> H2O: water<br/> Hb: haemoglobin<br/> Hct: haematocrit</sup> </p> <p><sup>IMV: intermittent mandatory ventilation<br/> NICU: neonatal intensive care unit<br/> O2: oxygen</sup> </p> </div> </div> <p><a href="./references#CD004868-bbs2-0001" title="AkisuM , TuzunS , ArslanogluS , YalazM , KultursayN . Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Medica Okayama2001;55(6):357‐62. [DOI: 10.18926/AMO/31997; PUBMED: 11779098] ">Akisu 2001</a> was a single centre study performed at University of Ege, Izmir, Turkey. </p> <p> <ul id="CD004868-list-0008"> <li> <p>Objective: To evaluate the effect of EPO on lipid peroxidation and the activities of erythrocyte antioxidant enzymes in very low birth weight (VLBW) infants. </p> </li> <li> <p>Population: Appropriately grown preterm infants with post menstrual age (PMA) &lt; 33 weeks' gestational age and birth weight &lt; 1500 grams. </p> </li> <li> <p>Intervention: The EPO group received high doses of EPO from day 10 of life, totaling 750 IU/kg/week (high dose). Infants in the control group received no placebo. All infants received 3 mg/kg/day (low dose) of elemental iron. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions.</p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0002" title="Al‐KharfyT , SmythJA , WadsworthL , KrystalG , FitzgeraldC , DavisJ , et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics1996;129(1):89‐96. [PUBMED: 8757567] SmythJA , AinsworthL , KrystalG , WadsworthL . Effect of erythropoietin therapy on oxygen dependency in premature infants. Pediatric Research2002;51(3):330 A. ">Al‐Kharfy 1996</a> was a single centre study performed in Canada. </p> <p> <ul id="CD004868-list-0009"> <li> <p>Objective: To determine whether treatment with EPO reduces transfusion requirements in preterm neonates at risk of having bronchopulmonary dysplasia (BDP) and requiring multiple transfusions. </p> </li> <li> <p>Population: Appropriately grown preterm infants with birth weight (BW) &lt; 1250 grams and having a 75% probability of having BPD determined on day 10 of life and postnatal age 10 to 17 days. </p> </li> <li> <p>Intervention: The EPO group received EPO 200 IU/kg body weight, by subcutaneous (sc) injection, on Monday, Wednesday and Friday for six weeks (600 IU/kg/week; high dose). The control group received sham injections. Oral ferrous sulphate solution was administered to the EPO group at 6 mg of elemental iron/kg/day (high dose) and the control group received 2 mg of elemental iron/kg/day (low dose). </p> </li> <li> <p>Outcomes assessed: Number of transfusions per infant, mortality, sepsis, retinopathy of prematurity (ROP) (stage ≥ 3), hypertension, BPD at 28 days of age. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0003" title="AtasayB , GunlemezA , AkarN , ArsanS . Does early erythropoietin therapy decrease transfusions in anemia of prematurity?. Indian Journal of Pediatrics2002;69(5):389‐91. [PUBMED: 12061670] ">Atasay 2002</a> was a single centre study performed in Turkey. </p> <p> <ul id="CD004868-list-0010"> <li> <p>Objective: To investigate the effect of early EPO treatment on induction of erythropoiesis and the need for transfusion in VLBW infants with acute neonatal problems. </p> </li> <li> <p>Population: Infants with BW &lt; 1500 grams and PMA &lt; 32 weeks' gestational age.</p> </li> <li> <p>Intervention: The EPO group received EPO 600 IU/kg/week (high dose) sc, at seven to ten days and continued over seven to eight weeks. The control group received no EPO, placebo, or iron. The EPO group was supplemented with oral iron (ferro glycine sulphate) at the dose of 3 mg/kg/day (low dose). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusion(s).</p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0004" title="BaderD , BlondheimO , JonasR , AdmoniO , Abend‐WingeM , ReichD , et al. Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity. Acta Paediatrica1996;85(4):496‐501. [PUBMED: 8740313] ">Bader 1996</a> was a two‐centre study performed in Israel. </p> <p> <ul id="CD004868-list-0011"> <li> <p>Objective: To assess whether an iron dose of 6 mg/kg/day is sufficient to maintain serum ferritin at adequate levels (as per authors). </p> </li> <li> <p>Population: Preterm infants with PMA &lt; 34 weeks' gestational age and BW &lt; 1750 grams and postnatal age three to five weeks. </p> </li> <li> <p>Intervention: The EPO group received EPO 300 IU/kg/day sc three times a week (900 IU/kg/week; high dose), for a total duration of four weeks. The control group received no placebo or other intervention. Two weeks into the study, elemental iron supplementation was begun in both groups at a dose of 6 mg/kg/day (high dose). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, side effects, sudden infant death syndrome (SIDS). </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a> was a single centre study performed in Iran. </p> <p> <ul id="CD004868-list-0012"> <li> <p>Objective: To evaluate the effectiveness of EPO treatment in preventing anaemia of prematurity. </p> </li> <li> <p>Population: Preterm infants of 24 to 31 weeks' postmenstrual age.</p> </li> <li> <p>Intervention: The study group 250 U rhEpo/kg BW (0.1 ml solution/kg BW) given sc 3 days a week every other day on Monday, Wednesday and Friday. (= 3 x 250 U/week = 750 IU/week; high EPO). The control group received equal volume normal saline 0.1 ml solution/kg BW. Infants in both groups were given oral ferrous sulphate, 4 mg/kg/day during the entire treatment period (4 mg/kg/day; low iron (&lt; 5 mg/kg/day). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusion(s), unspecified side effects. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0006" title="BechensteenAG , HagaP , HalvorsenS , WhitelawA , LiestolK , LindemannR , et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Archieves of Disease in Childhood1993;69(1 Spec No):19‐23. [PUBMED: 8346946] BechensteenAG , HalvorsenS , HagaP . Erythropoiesis during rapid growth. Role of erythropoietin and nutrition. Annals of the New York Academy of Sciences1994;718:339‐40. [PUBMED: 8185241] BechensteenAG , HalvorsenS , HagaP , CotesPM , LiestolK . Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatrica1996;85(4):490‐5. [PUBMED: 8346946] BechensteenAG , RefsumHE , HalvorsenS , HagaP , LiestolK . Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants. Pediatric Research1995;38(5):729‐32. [DOI: 10.1203/00006450‐199511000‐00016; PUBMED: 8552441] ">Bechensteen 1993</a> was a four‐centre study performed in Norway. </p> <p> <ul id="CD004868-list-0013"> <li> <p>Objective: To determine whether VLBW infants respond to EPO with increased erythropoiesis.</p> </li> <li> <p>Population: Preterm infants with BW 900 grams to 1400 grams at three weeks of age.</p> </li> <li> <p>Intervention: The EPO group received EPO 100 IU/kg three times a week (300 IU/kg/week; low dose) sc from three to seven weeks of age. The control group received neither EPO nor placebo. Oral iron 18 mg/day (high dose) regardless of weight, began at the start of the study (three weeks). If serum iron concentration fell below 16 micromol/L, the dose was increased to 36 mg/day. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, mortality, hypertension, neutropenia, side effects. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a> was a single centre study performed in the USA. </p> <p> <ul id="CD004868-list-0014"> <li> <p>Objective: To determine if EPO administration to neonates requiring surgery would stimulate erythropoiesis. </p> </li> <li> <p>Population: Neonates requiring surgery. Post‐natal age &lt; 28 days. The majority of infants were preterm and/or LBW. </p> </li> <li> <p>Intervention: The EPO group received EPO 200 IU/kg per day or 400 IU/kg sc three times weekly (high dose). The placebo group received an equal volume of normal saline if the infant was on total parenteral nutrition and, if not, a sham dose was given sc and a BandAid was placed over the sham injection site. Infants received oral iron supplementation when enteral feeds reached 60 mL/kg/day. </p> </li> <li> <p>Outcomes assessed: Volume transfused during hospitalisation (mL/kg), number of donors the infants was exposed to. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a> was a single centre study performed in Taiwan, Republic of China. </p> <p> <ul id="CD004868-list-0015"> <li> <p>Objective: To evaluate the safety and efficacy of EPO for the treatment of anaemia of prematurity. </p> </li> <li> <p>Population: Preterm infants with PMA ≤ 33 weeks' gestational age and BW ≤ 1750 grams, haemoglobin (Hb) &lt; 10 g/dL and haematocrit (Hct) &lt; 30%. </p> </li> <li> <p>Intervention: The EPO group (A) received 150 IU/kg iv twice a week (300 IU/kg/week; low dose); Group B received packed washed erythrocyte transfusion, when their Hb levels were &lt; 10 g/dL with signs and symptoms attributed to anaemia or who had a Hb level &lt; 8 g/dL even if asymptomatic; group C did not received EPO or erythrocyte transfusions (three infants excluded from total 19, as they received erythrocyte transfusion later because of frequent episodes of apnoea). All infants received oral elemental iron 3 mg/kg/day (low dose). Group A and C were included in this review. </p> </li> <li> <p>Outcomes assessed: Mortality, adverse effects.</p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a> was a single centre study performed in Italy. </p> <p> <ul id="CD004868-list-0016"> <li> <p>Objective: To evaluate the efficacy of EPO, establish the optimal dose, the age at which to start, the duration of the treatment, any adverse effects, and the reduction in red blood cell transfusions. </p> </li> <li> <p>Population: Preterm infants (BW &lt; 1500 grams and &lt; 33 weeks' postmenstrual age).</p> </li> <li> <p>Intervention: EPO group A received EPO 150 IU/kg/week sc low dose ; EPO group B received 300 IU/kg/week sc low dose; the control group (group C) received no treatment. All groups received oral iron 4 mg/kg/day (low dose). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, total volume (mL/kg) of blood transfused per infant (means but no standard deviation (SD) provided), side effects. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0010" title="DonatoH , RendoP , VivasR , SchvartzmanG , DigregorioJ , VainN . Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double‐blind, placebo‐controlled trial comparing three different doses. International Journal of Pediatric Hematology/Oncology1996;3:279‐85. ">Donato 1996</a> was a single centre study performed in Argentina. </p> <p> <ul id="CD004868-list-0017"> <li> <p>Objective: To assess the efficacy of three different doses of recombinant human EPO (rHuEPO) to reduce the need for transfusion in preterm infants with BW &lt; 1500 grams. </p> </li> <li> <p>Population: Preterm infants with PMA &lt; 34 weeks' gestational age and BW &lt; 1500 grams.</p> </li> <li> <p>Intervention: The placebo group (A) received human seroalbumin. The three EPO groups: Group B received EPO 50 IU/kg (150 IU/kg/week; low dose), Group C received EPO 100 IU/kg (300 IU/kg/week; low dose) and Group D received EPO 250 IU/kg (750 IU/kg/week; high dose) sc during eight consecutive weeks. All participants were given oral iron 6 mg/kg/day (high dose) and folic acid (2 mg/day) supplements, starting on day 15 of age and continuing during whole treatment period. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, average number of transfusions per infant during treatment, mortality, mean length of hospitalisation time, side effects, hypertension, SIDS. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0011" title="EmmersonAJ , ColesHJ , SternCM , PearsonTC . Double blind trial of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood1993;68(3 Spec No):291‐6. [PUBMED: 8466265] ">Emmerson 1993</a> was a single centre study performed in the UK. </p> <p> <ul id="CD004868-list-0018"> <li> <p>Objective: To investigate the safety and efficacy of EPO for the prevention of anaemia of prematurity. </p> </li> <li> <p>Population: Infants between 27 and 33 weeks' postmenstrual age.</p> </li> <li> <p>Intervention: The EPO group received low dose EPO (between 50 and 150 IU) twice a week from seven days of age and the placebo group received 4% albumin from seven days of age until discharge home. All infants received iron (6.25 mg) in the form of ferrous glycine sulphate from four weeks of age (high dose). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, volume transfused (mL/kg), mortality, hospital stay, SIDS, neutropenia. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a> and <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a> was a single centre study performed in Greece. </p> <p> <ul id="CD004868-list-0019"> <li> <p>Objective: To stimulate erythrocyte production by the use of EPO and thereby decrease the requirement for red blood cell transfusions. </p> </li> <li> <p>Population: Preterm infants with BWs ≤ 1300 grams, postnatal age &gt; 20 days.</p> </li> <li> <p>Intervention: The EPO group received EPO 300 IU/kg body weight, three times a week (900 IU/kg/week; high dose) from 20 days of age for six to eight weeks. The control group did not received any placebo. All infants received oral elemental iron 10 mg/kg/day (high dose). </p> </li> <li> <p>Outcomes assessed: Mortality, side effects, hypertension, neutropenia.</p> </li> <li> <p>We treated this report as two separate studies; Under <a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a> we reported on the 32 infants weighing &lt; 1000 g and under <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a> we reported on the 36 infants weighing 1000 to 1300 grams. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a> was a study conducted in four neonatal intensive care units (NICU) in Yorkshire, England. </p> <p> <ul id="CD004868-list-0020"> <li> <p>Objective: To evaluate the role of EPO in reducing iron supplementation, which may exacerbate free radical change, leading to lung disease. </p> </li> <li> <p>Population: Preterm infants with postmenstrual age ≤ 32 weeks and/or BW ≤ 1500 grams, requirement for mechanical ventilation and/or supplemental oxygen at birth. Postnatal age seven to 14 days. </p> </li> <li> <p>Intervention: The EPO group received 480 IU/kg/week (low dose) and the control group received placebo (4% human albumin) starting at seven to 14 days of age. All infants received oral iron (3.0 mg/kg/day) (low dose) from four weeks after birth. </p> </li> <li> <p>Outcomes assessed: Mortality, BPD (at 36 weeks' postmenstrual age), number of blood transfusions per infant (medians provided), SIDS. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0015" title="Javier ManchonG , Natal PujolA , Coroleu LletgetW , Zuasnabar CotroA , Badia BarnusellJ , Junca PieraJ , et al. Randomized multi‐centre trial of the administration of erythropoietin in anemia of prematurity [Estudio multicentrico aleatorizado de administracion de eritropoyetina en la anemia de la prematuridad]. Anales Espanoles de Pediatria1997;46(6):587‐92. [PUBMED: 9297428] ">Javier Manchon 1997</a> was a multi‐centre study involving three centres in Barcelona, Spain. </p> <p> <ul id="CD004868-list-0021"> <li> <p>Objective: To test the therapeutic effect of EPO on anaemia of prematurity.</p> </li> <li> <p>Population: Preterm infants &lt; 34 weeks' postmenstrual age, who at 28 days after birth had Hb levels &lt; 10.5 g/dL. </p> </li> <li> <p>Intervention: The EPO group received high dose EPO (200 IU/kg/day) three days a week for four weeks and ferrous sulphate 4 mg/kg/day (low dose). The control infants did not receive placebo, EPO, or iron. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions between 30 and 60 days of age. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a> was a single centre study performed in the USA. </p> <p> <ul id="CD004868-list-0022"> <li> <p>Objective: To determine whether enterally dosed EPO stimulates erythropoiesis in preterm infants. </p> </li> <li> <p>Population: Preterm infants with BW between 700 to 1500 grams and receiving at least 30 mL/kg per day of enteral feeding. </p> </li> <li> <p>Intervention: The EPO group received 1000 IU/kg (enterally) per day divided into two daily feedings (7000 IU/kg/week; high dose), for 14 days. The placebo group received 5% dextrose in water for 14 days. All participants received supplemental iron (iron dextran, 1.0 mg/kg/day, or enteral ferrous sulphate 6 mg/kg/day (high dose)). </p> </li> <li> <p>Outcomes assessed: Phlebotomy loss (mL) and packed red blood cell transfusion volume (mL). Evidence of feeding intolerance and other adverse effects. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0017" title="KivivuoriSM , VirtanenM , RaivioKO , ViinikkaL , SiimesMA . Oral iron is sufficient for erythropoietin treatment of very low birth‐weight infants. European Journal of Pediatrics1999;158(2):147‐51. [PUBMED: 10048613] ">Kivivuori 1999</a> was a four‐centre study performed in Helsinki and Espoo, Finland. </p> <p> <ul id="CD004868-list-0023"> <li> <p>Objective: To compare oral and intramuscular routes of administration of iron in EPO treated VLBW infants. </p> </li> <li> <p>Population: VLBW infants (birth weight ranged from 625 to 1470 grams).</p> </li> <li> <p>Intervention: One EPO group received EPO 300 IU/kg sc three times/week, 900 IU/kg/week (high dose) sc and oral iron 6 mg/kg/day (high dose). Another EPO group received EPO 900 IU/kg/week and weekly intramuscular (im) iron 12 mg/kg (high dose). The control group received im iron 12 mg/kg/week but no EPO. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, adverse effects.</p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0018" title="KumarP , ShankaranS , KrishnanRG . Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double‐blind, placebo‐controlled trial. Journal of Perinatology1998;18(3):173‐7. [PUBMED: 9659643] ">Kumar 1998</a> was a single centre study performed in the USA. </p> <p> <ul id="CD004868-list-0024"> <li> <p>Objective: To evaluate the efficacy and safety of EPO in VLBW infants with anaemia of prematurity. </p> </li> <li> <p>Population: Preterm infants (PMA &lt; 32 weeks, BW &lt; 1250 grams) with anaemia of prematurity.</p> </li> <li> <p>Intervention: The EPO group received 300 IU/kg/dose of EPO sc twice a week (600 IU/kg/week; high dose) for six weeks. The control group received an identical volume of placebo suspension (normal saline). All infants received elemental iron 6 mg/kg/day (high dose). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, number of erythrocyte transfusions (per infant), entry to discharge duration (days), side effects. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0019" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [PUBMED: 12091844] ">Maier 2002</a> was a multicentre study performed in 14 centres in four European countries (Belgium, France, Germany, Switzerland). </p> <p> <ul id="CD004868-list-0025"> <li> <p>Objective: To investigate whether EPO reduces the need for transfusions in extremely low birth weight (ELBW) infants and to determine the optimal dose of treatment. </p> </li> <li> <p>Population: Preterm infants with BW 500 to 999 grams.</p> </li> <li> <p>Intervention: The EPO group received EPO 200 IU/kg/dose three times a week sc (600 IU/kg/week, high dose). The volume was increased by the equivalent of 50 IU/kg per dose if the haematocrit declined by 6% during any two‐week period during the trial, but was withheld if the haematocrit was &gt; 45%. The control group received an identical volume of placebo. Enteral iron 3 mg/kg/day (low dose) was given to all infants from days three to five and was increased at days 12 to 14 to 6 mg/kg/day (high dose) and to 9 mg/kg/day (high dose) at days 24 to 26 of life. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, donor exposure, mortality during hospital stay, necrotising enterocolitis (NEC), IVH, periventricular leukomalacia (PVL), ROP, days in oxygen, days in NICU, days in hospital. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0020" title="MeyerMP , HaworthC , McNeillL . Is the use of recombinant human erythropoietin in anemia of prematurity cost‐effective?. South African Medical Journal1996;86(3):251‐3. [PUBMED: 8658295] MeyerMP , MeyerJH , CommerfordA , HannFM , SiveAA , MollerG , et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double‐blind, placebo‐controlled study. Pediatrics1994;93(6 Pt 1):918‐23. [PUBMED: 8190577] ">Meyer 1994</a> was a single centre study performed in South Africa. </p> <p> <ul id="CD004868-list-0026"> <li> <p>Objective: To assess the efficacy of EPO in the treatment of anaemia of prematurity.</p> </li> <li> <p>Population: Preterm infants (≤ 32 weeks' postmenstrual age, weight ≤ 1500 grams, postnatal age two to eight weeks, central haematocrit Hct ≤ 35%). </p> </li> <li> <p>Intervention: The EPO group received high dose EPO (200 IU/kg three times a week; 600 IU/kg/week). The control group received an identical volume of placebo. All infants received 3 mg/kg/day of iron (low dose). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, sepsis, NEC, SIDS.</p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0021" title="KasperDC , WidnessJA , HaidenN , Berger A. HaydeM , PollakA , et al. Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram. Neonatology2009;95(2):164‐71. [PUBMED: 18776731] PollakA , HaydeM , HaynM , HerknerK , LombardKA , LubecG , et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin‐treated premature infants. Pediatrics2001;107(1):78‐85. [PUBMED: 11134438] ">Pollak 2001</a> was a single centre study conducted in Vienna, Austria. </p> <p> <ul id="CD004868-list-0027"> <li> <p>Objective: To test the efficacy and safety of combining intravenous iron in amounts approximately the in‐utero accretion rate and the postnatal iron loss with EPO in VLBW infants. </p> </li> <li> <p>Population: Preterm infants &lt; 31 weeks' postmenstrual age and &lt; 1300 grams birth weight not treated with red blood cell transfusions during the study period. </p> </li> <li> <p>Intervention: During a three‐day run‐in baseline period, 9 mg/kg/day of iron poly maltose complex (high dose) was administered to all participants in all groups. This was followed by a treatment period during which participants received: 1) the same oral iron supplementation dose alone (oral iron group ‐ control group); 2) 300 IU/kg/day of EPO iv at three‐day intervals (600 IU/kg/week, high dose) along with the same oral iron supplement as the oral iron group (EPO + oral iron group); or 3) 2 mg of intravenous iron sucrose/kg/day + EPO as in group two (iv iron + EPO group). To maintain comparability of iron intake among the three groups, this last group also received EPO and oral iron in an identical manner to the EPO + oral iron group. </p> </li> <li> <p>Outcomes assessed: Mortality, sepsis, ROP, BPD (oxygen dependency at 36 weeks' postmenstrual age). </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0022" title="ReiterPD , RosenbergAA , ValuckR , NovakK . Effect of short‐term erythropoietin therapy in anemic premature infants. Journal of Perinatology2005;25(2):125‐9. [PUBMED: 15526012] ">Reiter 2005</a> was a single centre study performed in the USA. </p> <p> <ul id="CD004868-list-0028"> <li> <p>Objective: To determine the effectiveness of a 10‐day EPO course in preterm infants.</p> </li> <li> <p>Population: Preterm infants &lt; 32 weeks' postmenstrual age, haematocrit ≤ 28%, post‐conceptual age of &lt; 48 weeks or five months chronological age. </p> </li> <li> <p>Intervention: The EPO group received 300 IU/kg/day (high dose) and 6 mg/kg/day of enteral iron (high dose) versus iron only. Both groups received the intervention for 10 days. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, volume of red blood cells required (mL/kg). </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0023" title="RochaVL , BenjaminAC , ProcianoyRS . The effect of recombinant human erythropoietin on the treatment of anemia of prematurity. Journal de Pediatria2001;77(2):75‐83. [PUBMED: 14647595] ">Rocha 2001</a> was a single centre study performed in Brazil. </p> <p> <ul id="CD004868-list-0029"> <li> <p>Objective: To assess the efficacy of EPO for the prevention and treatment of anaemia of prematurity. </p> </li> <li> <p>Population: Preterm infants with PMA up to 33 weeks, BW up to 1550 grams and postnatal age between 10 and 35 days. </p> </li> <li> <p>Intervention: The two EPO groups received either daily doses of 100 IU/kg of EPO or twice weekly doses of 350 IU/kg (700 IU/kg/week, high dose). The EPO groups were given iron (ferrous sulphate) 3 mg/kg/day enterally, and increased to 6 mg/kg/day in the second week of treatment. In the control group, iron supplementation was initiated around the 30th day of life. The control group did not receive any placebo. </p> </li> <li> <p>Outcomes assessed: Mean number of blood transfusions per participant (no SD provided), two or more blood transfusions per participant. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a> was a single centre study performed in Italy. </p> <p> <ul id="CD004868-list-0030"> <li> <p>Objective: To assess the effectiveness of rhEPO.</p> </li> <li> <p>Population: Infants with PMA ≤ 30 weeks and those infants of 31 to 34 weeks' PMA suffering from respiratory distress syndrome and requiring mechanical ventilation. </p> </li> <li> <p>Intervention: Treated infants received rhEPO doses of 300 IU/kg body weight sc on each Monday, Wednesday and Friday from the 2nd to the 7th week of life (high dose). Iron supplementation (Intrafer‐Geymonat) was given at a dose of 1 mg/kg per day iv from the 2nd to the 4th week (low dose); thereafter, 12 mg/kg/day orally until the 7th week of life. </p> </li> <li> <p>Outcomes assessed: Retinopathy of prematurity (stage 1 to 2 and stage 3 to 4), IVH (&gt; grade 2), sepsis, NEC, number of infants transfused, number of transfusions per infant. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0025" title="RonnestadA , MoePJ , BreivikN . Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anaemia of prematurity. Acta Paediatrica1995;84(7):809‐11. [PUBMED: 7549303] ">Ronnestad 1995</a> was a single centre study performed in Norway. </p> <p> <ul id="CD004868-list-0031"> <li> <p>Objective: To investigate whether EPO given to infants &lt; 32 weeks' gestational age, fed with their own mother's milk supplemented with a bovine milk protein and electrolyte fortifier together with moderate iron supplementation, would ameliorate the anaemia and thus reduce the need for bred blood cell transfusions after the second week of life. </p> </li> <li> <p>Population: Preterm infants, PMA &lt; 32 weeks. Age 14 to 22 days.</p> </li> <li> <p>Intervention: The EPO group received EPO 150 IU/kg three times per week (450 IU/kg/week; low dose) or placebo. All infants received 4 mg/kg/day of iron (low dose) as ferrous fumarase. </p> </li> <li> <p>Outcomes assessed: Neutropenia.</p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a> was a single centre study performed in Turkey. </p> <p> <ul id="CD004868-list-0032"> <li> <p>Objective: To determine whether EPO would prevent anaemia of prematurity and reduce the need for transfusion in infants with VLBW. </p> </li> <li> <p>Population: Preterm infants with PMA ≤ 32 weeks, BW of ≤ 1250 grams. Postnatal age at the first dose was two to four weeks. </p> </li> <li> <p>Intervention: The EPO group received 200 IU/kg sc three times weekly (600 IU/kg/week, high dose), for four weeks. The control group received an equivalent volume of placebo sc, three times weekly, for four weeks. All infants received oral supplements of elemental iron (3 mg/kg/day) (low dose) during the study period. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, number of blood transfusions per infant, NEC, IVH, major adverse events. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a> was a three‐centre study performed in the USA. </p> <p> <ul id="CD004868-list-0033"> <li> <p>Objective: Not stated.</p> </li> <li> <p>Population: Preterm infants with BWs ≤ 1250 grams.</p> </li> <li> <p>Intervention: The EPO group received EPO 100 IU/kg, twice each week (200 IU/kg/week; low dose) for six weeks. The control group received intravenous injections of an identical volume of placebo twice each week for six weeks. All infants received 3 mg/kg/day of oral iron (low dose) and continued at the discretion of the attending physician. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, mortality, NEC, hypertension, neutropenia, side effects. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0028" title="ShannonKM , MentzerWC , AbelsRI , WertzM , Thayer‐MoriyamaJ , LiWY , et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. Journal of Pediatrics1992;120(4 Pt 1):586‐92. ">Shannon 1992</a> was a single centre study performed in the USA. </p> <p> <ul id="CD004868-list-0034"> <li> <p>Objective: Not stated.</p> </li> <li> <p>Population: Preterm infants with PMA &lt; 33 weeks and BW &lt; 1250 grams.</p> </li> <li> <p>Intervention: The EPO group received EPO 100 IU/kg, 5 times a week (500 IU/kg/week; high dose). The control group received an identical volume of placebo suspension, five times a week. Oral iron was started in all infants at 3 mg/kg/day (low dose), divided into three doses and given between feedings. The iron dose was increased to 6 mg/kg/day (high dose) for infants who were tolerating full caloric feedings. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, major adverse events.</p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a> was a multi‐centre study at 11 centres in the USA. </p> <p> <ul id="CD004868-list-0035"> <li> <p>Objective: To assess whether treatment with EPO would stimulate erythropoiesis and thereby reduce the need for erythrocyte transfusions in preterm infants. </p> </li> <li> <p>Population: Preterm infants with PMA &lt; 31 weeks with BW of ≤ 1250 grams.</p> </li> <li> <p>Intervention: The EPO group received 100 IU/kg/day (from Monday through Friday (500 IU/kg/week; high dose)) for six weeks or until the infants were ready to be discharged home. Doses of EPO (or placebo) were adjusted weekly according to changes in body weight. The control group received an identical volume of placebo suspension. Participants received oral iron supplements at study entry to achieve a total enteral intake of 3 mg/kg/day of elemental iron (low dose). Total iron intake was increased to 6 mg/kg/day (high dose) when the infants tolerated full caloric feeding enterally. </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood cell transfusions, mean number of erythrocyte transfusions per infant, mortality, sepsis, NEC, ROP, hypertension, SIDS, side effects. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0030" title="WhitehallJS , PatoleSK , CampbellP . Recombinant human erythropoietin in anemia of prematurity. Indian Pediatrics1999;36(1):17‐27. [PUBMED: 10709119] ">Whitehall 1999</a> was a single centre study conducted in Australia. </p> <p> <ul id="CD004868-list-0036"> <li> <p>Objective: To evaluate safety and efficacy of EPO in reducing the need for red cell transfusions in anaemia of prematurity. </p> </li> <li> <p>Population: Infants with PMA ≤ 32 weeks.</p> </li> <li> <p>Intervention: Infants in the EPO group received 400 IU/kg every second day x 10 doses (high dose). Infants in the control group received no placebo. Both groups received 3 mg/kg/day of iron (low dose) increased to 6 mg/kg/day (high dose), as tolerated. </p> </li> <li> <p>Outcomes assessed: Total volume (mL/kg) of blood transfused, number of transfusions per infant, mortality during hospital stay. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0031" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm. Acta Neonatologica Japonica1999;35(4):755‐61. ">Yamada 1999a</a> was a single centre study conducted in Japan. </p> <p> <ul id="CD004868-list-0037"> <li> <p>Objective: To assess the efficacy of EPO in the treatment of anaemia of prematurity.</p> </li> <li> <p>Population: Infants with BW 1000 to 1499 grams, PMA &lt; 33 weeks, haemoglobin &lt; 12 g/dL and oral milk intake &gt; 50 mL/kg/day. </p> </li> <li> <p>Intervention: The EPO group received EPO (200 IU/kg twice a week, low dose) for eight weeks and the control group received no study drug or placebo. All infants received 3 mg/kg/day of oral iron (low dose). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood transfusions, total volume of blood transfused (mL/infant), number of transfusions per infant, side effects. </p> </li> </ul> </p> <p><a href="./references#CD004868-bbs2-0032" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm. Acta Neonatologica Japonica1999;35(4):762‐7. ">Yamada 1999b</a> was a single centre study conducted in Japan. </p> <p> <ul id="CD004868-list-0038"> <li> <p>Objective: To assess the efficacy of EPO in the treatment of anaemia of prematurity.</p> </li> <li> <p>Population: Infants with BW 500 to 999 grams, PMA &lt; 33 weeks, haemoglobin &lt; 13 g/dL and oral milk intake &gt; 50 mL/kg/day. </p> </li> <li> <p>Intervention: The EPO group received low dose EPO (200 IU/kg twice a week) for eight weeks and the control group received no study drug or placebo. All infants received 3 mg/kg/day of oral iron (low dose). </p> </li> <li> <p>Outcomes assessed: Use of one or more red blood transfusions, total volume of blood transfused (mL/infant), number of transfusions per infant, side effects. </p> </li> </ul> </p> <p>Three different routes of administration were used; subcutaneous (sc) (<a href="./references#CD004868-bbs2-0028" title="ShannonKM , MentzerWC , AbelsRI , WertzM , Thayer‐MoriyamaJ , LiWY , et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. Journal of Pediatrics1992;120(4 Pt 1):586‐92. ">Shannon 1992</a>; <a href="./references#CD004868-bbs2-0006" title="BechensteenAG , HagaP , HalvorsenS , WhitelawA , LiestolK , LindemannR , et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Archieves of Disease in Childhood1993;69(1 Spec No):19‐23. [PUBMED: 8346946] BechensteenAG , HalvorsenS , HagaP . Erythropoiesis during rapid growth. Role of erythropoietin and nutrition. Annals of the New York Academy of Sciences1994;718:339‐40. [PUBMED: 8185241] BechensteenAG , HalvorsenS , HagaP , CotesPM , LiestolK . Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatrica1996;85(4):490‐5. [PUBMED: 8346946] BechensteenAG , RefsumHE , HalvorsenS , HagaP , LiestolK . Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants. Pediatric Research1995;38(5):729‐32. [DOI: 10.1203/00006450‐199511000‐00016; PUBMED: 8552441] ">Bechensteen 1993</a>; <a href="./references#CD004868-bbs2-0011" title="EmmersonAJ , ColesHJ , SternCM , PearsonTC . Double blind trial of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood1993;68(3 Spec No):291‐6. [PUBMED: 8466265] ">Emmerson 1993</a>; <a href="./references#CD004868-bbs2-0020" title="MeyerMP , HaworthC , McNeillL . Is the use of recombinant human erythropoietin in anemia of prematurity cost‐effective?. South African Medical Journal1996;86(3):251‐3. [PUBMED: 8658295] MeyerMP , MeyerJH , CommerfordA , HannFM , SiveAA , MollerG , et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double‐blind, placebo‐controlled study. Pediatrics1994;93(6 Pt 1):918‐23. [PUBMED: 8190577] ">Meyer 1994</a>; <a href="./references#CD004868-bbs2-0031" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm. Acta Neonatologica Japonica1999;35(4):755‐61. ">Yamada 1999a</a>; <a href="./references#CD004868-bbs2-0032" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm. Acta Neonatologica Japonica1999;35(4):762‐7. ">Yamada 1999b</a>; <a href="./references#CD004868-bbs2-0025" title="RonnestadA , MoePJ , BreivikN . Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anaemia of prematurity. Acta Paediatrica1995;84(7):809‐11. [PUBMED: 7549303] ">Ronnestad 1995</a>; <a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>; <a href="./references#CD004868-bbs2-0002" title="Al‐KharfyT , SmythJA , WadsworthL , KrystalG , FitzgeraldC , DavisJ , et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics1996;129(1):89‐96. [PUBMED: 8757567] SmythJA , AinsworthL , KrystalG , WadsworthL . Effect of erythropoietin therapy on oxygen dependency in premature infants. Pediatric Research2002;51(3):330 A. ">Al‐Kharfy 1996</a>; <a href="./references#CD004868-bbs2-0004" title="BaderD , BlondheimO , JonasR , AdmoniO , Abend‐WingeM , ReichD , et al. Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity. Acta Paediatrica1996;85(4):496‐501. [PUBMED: 8740313] ">Bader 1996</a>; <a href="./references#CD004868-bbs2-0010" title="DonatoH , RendoP , VivasR , SchvartzmanG , DigregorioJ , VainN . Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double‐blind, placebo‐controlled trial comparing three different doses. International Journal of Pediatric Hematology/Oncology1996;3:279‐85. ">Donato 1996</a>; <a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a>; <a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a>; <a href="./references#CD004868-bbs2-0015" title="Javier ManchonG , Natal PujolA , Coroleu LletgetW , Zuasnabar CotroA , Badia BarnusellJ , Junca PieraJ , et al. Randomized multi‐centre trial of the administration of erythropoietin in anemia of prematurity [Estudio multicentrico aleatorizado de administracion de eritropoyetina en la anemia de la prematuridad]. Anales Espanoles de Pediatria1997;46(6):587‐92. [PUBMED: 9297428] ">Javier Manchon 1997</a>; <a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a>; <a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a>; <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a>; <a href="./references#CD004868-bbs2-0018" title="KumarP , ShankaranS , KrishnanRG . Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double‐blind, placebo‐controlled trial. Journal of Perinatology1998;18(3):173‐7. [PUBMED: 9659643] ">Kumar 1998</a>; <a href="./references#CD004868-bbs2-0017" title="KivivuoriSM , VirtanenM , RaivioKO , ViinikkaL , SiimesMA . Oral iron is sufficient for erythropoietin treatment of very low birth‐weight infants. European Journal of Pediatrics1999;158(2):147‐51. [PUBMED: 10048613] ">Kivivuori 1999</a>; <a href="./references#CD004868-bbs2-0030" title="WhitehallJS , PatoleSK , CampbellP . Recombinant human erythropoietin in anemia of prematurity. Indian Pediatrics1999;36(1):17‐27. [PUBMED: 10709119] ">Whitehall 1999</a>; <a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a>; <a href="./references#CD004868-bbs2-0001" title="AkisuM , TuzunS , ArslanogluS , YalazM , KultursayN . Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Medica Okayama2001;55(6):357‐62. [DOI: 10.18926/AMO/31997; PUBMED: 11779098] ">Akisu 2001</a>; <a href="./references#CD004868-bbs2-0023" title="RochaVL , BenjaminAC , ProcianoyRS . The effect of recombinant human erythropoietin on the treatment of anemia of prematurity. Journal de Pediatria2001;77(2):75‐83. [PUBMED: 14647595] ">Rocha 2001</a>; <a href="./references#CD004868-bbs2-0003" title="AtasayB , GunlemezA , AkarN , ArsanS . Does early erythropoietin therapy decrease transfusions in anemia of prematurity?. Indian Journal of Pediatrics2002;69(5):389‐91. [PUBMED: 12061670] ">Atasay 2002</a>; <a href="./references#CD004868-bbs2-0022" title="ReiterPD , RosenbergAA , ValuckR , NovakK . Effect of short‐term erythropoietin therapy in anemic premature infants. Journal of Perinatology2005;25(2):125‐9. [PUBMED: 15526012] ">Reiter 2005</a>; <a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a>; <a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a>), intravenous (iv) (<a href="./references#CD004868-bbs2-0021" title="KasperDC , WidnessJA , HaidenN , Berger A. HaydeM , PollakA , et al. Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram. Neonatology2009;95(2):164‐71. [PUBMED: 18776731] PollakA , HaydeM , HaynM , HerknerK , LombardKA , LubecG , et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin‐treated premature infants. Pediatrics2001;107(1):78‐85. [PUBMED: 11134438] ">Pollak 2001</a>; <a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a>; <a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a>;), oral (<a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a>), or iv or sc (<a href="./references#CD004868-bbs2-0019" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [PUBMED: 12091844] ">Maier 2002</a>). The dose of EPO varied from 150 IU/kg/week (<a href="./references#CD004868-bbs2-0010" title="DonatoH , RendoP , VivasR , SchvartzmanG , DigregorioJ , VainN . Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double‐blind, placebo‐controlled trial comparing three different doses. International Journal of Pediatric Hematology/Oncology1996;3:279‐85. ">Donato 1996</a>; <a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a>) to 2100 IU/kg/week (<a href="./references#CD004868-bbs2-0022" title="ReiterPD , RosenbergAA , ValuckR , NovakK . Effect of short‐term erythropoietin therapy in anemic premature infants. Journal of Perinatology2005;25(2):125‐9. [PUBMED: 15526012] ">Reiter 2005</a>) when given subcutaneously. When given intravenously, the dose varied from 200 IU/kg/week (<a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a>) to 300 IU/kg/week (<a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a>). <a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a> provided 7000 IU/kg/week enterally. </p> <p>Different EPO preparations were used; Recormon (Boehringer‐Mannheim, Germany) (<a href="./references#CD004868-bbs2-0001" title="AkisuM , TuzunS , ArslanogluS , YalazM , KultursayN . Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Medica Okayama2001;55(6):357‐62. [DOI: 10.18926/AMO/31997; PUBMED: 11779098] ">Akisu 2001</a>); Eprex (provided by Cilag Zug, Switzerland, Ortho Pharmaceutical Canada Ltd., Janssen‐Cilag or Guler Pharmaceutical Corp, Istanbul, Turkey) (<a href="./references#CD004868-bbs2-0006" title="BechensteenAG , HagaP , HalvorsenS , WhitelawA , LiestolK , LindemannR , et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Archieves of Disease in Childhood1993;69(1 Spec No):19‐23. [PUBMED: 8346946] BechensteenAG , HalvorsenS , HagaP . Erythropoiesis during rapid growth. Role of erythropoietin and nutrition. Annals of the New York Academy of Sciences1994;718:339‐40. [PUBMED: 8185241] BechensteenAG , HalvorsenS , HagaP , CotesPM , LiestolK . Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatrica1996;85(4):490‐5. [PUBMED: 8346946] BechensteenAG , RefsumHE , HalvorsenS , HagaP , LiestolK . Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants. Pediatric Research1995;38(5):729‐32. [DOI: 10.1203/00006450‐199511000‐00016; PUBMED: 8552441] ">Bechensteen 1993</a>; <a href="./references#CD004868-bbs2-0011" title="EmmersonAJ , ColesHJ , SternCM , PearsonTC . Double blind trial of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood1993;68(3 Spec No):291‐6. [PUBMED: 8466265] ">Emmerson 1993</a>; <a href="./references#CD004868-bbs2-0020" title="MeyerMP , HaworthC , McNeillL . Is the use of recombinant human erythropoietin in anemia of prematurity cost‐effective?. South African Medical Journal1996;86(3):251‐3. [PUBMED: 8658295] MeyerMP , MeyerJH , CommerfordA , HannFM , SiveAA , MollerG , et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double‐blind, placebo‐controlled study. Pediatrics1994;93(6 Pt 1):918‐23. [PUBMED: 8190577] ">Meyer 1994</a>; <a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a>; <a href="./references#CD004868-bbs2-0025" title="RonnestadA , MoePJ , BreivikN . Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anaemia of prematurity. Acta Paediatrica1995;84(7):809‐11. [PUBMED: 7549303] ">Ronnestad 1995</a>; <a href="./references#CD004868-bbs2-0002" title="Al‐KharfyT , SmythJA , WadsworthL , KrystalG , FitzgeraldC , DavisJ , et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics1996;129(1):89‐96. [PUBMED: 8757567] SmythJA , AinsworthL , KrystalG , WadsworthL . Effect of erythropoietin therapy on oxygen dependency in premature infants. Pediatric Research2002;51(3):330 A. ">Al‐Kharfy 1996</a>; <a href="./references#CD004868-bbs2-0004" title="BaderD , BlondheimO , JonasR , AdmoniO , Abend‐WingeM , ReichD , et al. Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity. Acta Paediatrica1996;85(4):496‐501. [PUBMED: 8740313] ">Bader 1996</a>; <a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a>; <a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a>; <a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a>; <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a>; <a href="./references#CD004868-bbs2-0017" title="KivivuoriSM , VirtanenM , RaivioKO , ViinikkaL , SiimesMA . Oral iron is sufficient for erythropoietin treatment of very low birth‐weight infants. European Journal of Pediatrics1999;158(2):147‐51. [PUBMED: 10048613] ">Kivivuori 1999</a>; <a href="./references#CD004868-bbs2-0030" title="WhitehallJS , PatoleSK , CampbellP . Recombinant human erythropoietin in anemia of prematurity. Indian Pediatrics1999;36(1):17‐27. [PUBMED: 10709119] ">Whitehall 1999</a>; <a href="./references#CD004868-bbs2-0003" title="AtasayB , GunlemezA , AkarN , ArsanS . Does early erythropoietin therapy decrease transfusions in anemia of prematurity?. Indian Journal of Pediatrics2002;69(5):389‐91. [PUBMED: 12061670] ">Atasay 2002</a> ); Amgen (<a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a>), Eogen alpha (Amgen, Inc. Thousand Oaks, CA, USA) (<a href="./references#CD004868-bbs2-0022" title="ReiterPD , RosenbergAA , ValuckR , NovakK . Effect of short‐term erythropoietin therapy in anemic premature infants. Journal of Perinatology2005;25(2):125‐9. [PUBMED: 15526012] ">Reiter 2005</a>); unnamed products (<a href="./references#CD004868-bbs2-0028" title="ShannonKM , MentzerWC , AbelsRI , WertzM , Thayer‐MoriyamaJ , LiWY , et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. Journal of Pediatrics1992;120(4 Pt 1):586‐92. ">Shannon 1992</a>; <a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>; <a href="./references#CD004868-bbs2-0015" title="Javier ManchonG , Natal PujolA , Coroleu LletgetW , Zuasnabar CotroA , Badia BarnusellJ , Junca PieraJ , et al. Randomized multi‐centre trial of the administration of erythropoietin in anemia of prematurity [Estudio multicentrico aleatorizado de administracion de eritropoyetina en la anemia de la prematuridad]. Anales Espanoles de Pediatria1997;46(6):587‐92. [PUBMED: 9297428] ">Javier Manchon 1997</a>; <a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a>; <a href="./references#CD004868-bbs2-0018" title="KumarP , ShankaranS , KrishnanRG . Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double‐blind, placebo‐controlled trial. Journal of Perinatology1998;18(3):173‐7. [PUBMED: 9659643] ">Kumar 1998</a>; <a href="./references#CD004868-bbs2-0031" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm. Acta Neonatologica Japonica1999;35(4):755‐61. ">Yamada 1999a</a>; <a href="./references#CD004868-bbs2-0032" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm. Acta Neonatologica Japonica1999;35(4):762‐7. ">Yamada 1999b</a>; <a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a>; <a href="./references#CD004868-bbs2-0023" title="RochaVL , BenjaminAC , ProcianoyRS . The effect of recombinant human erythropoietin on the treatment of anemia of prematurity. Journal de Pediatria2001;77(2):75‐83. [PUBMED: 14647595] ">Rocha 2001</a>; <a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a>; <a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a>), NeoRecormon (F. Hofman‐La Roche, Basel, Switzerland) (<a href="./references#CD004868-bbs2-0019" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [PUBMED: 12091844] ">Maier 2002</a>), Erypo (Janssen‐Cilag Pharma, Vienna, Austria) (<a href="./references#CD004868-bbs2-0021" title="KasperDC , WidnessJA , HaidenN , Berger A. HaydeM , PollakA , et al. Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram. Neonatology2009;95(2):164‐71. [PUBMED: 18776731] PollakA , HaydeM , HaynM , HerknerK , LombardKA , LubecG , et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin‐treated premature infants. Pediatrics2001;107(1):78‐85. [PUBMED: 11134438] ">Pollak 2001</a>), Hemax (Bio Sidus, S. A.) (<a href="./references#CD004868-bbs2-0010" title="DonatoH , RendoP , VivasR , SchvartzmanG , DigregorioJ , VainN . Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double‐blind, placebo‐controlled trial comparing three different doses. International Journal of Pediatric Hematology/Oncology1996;3:279‐85. ">Donato 1996</a>) and PDpoietin (Pooyesh Darou Inc, Iran) (<a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a>). </p> <p>Three studies did not state that guidelines for red blood cell transfusions were in place (<a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a>; <a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a>; <a href="./references#CD004868-bbs2-0001" title="AkisuM , TuzunS , ArslanogluS , YalazM , KultursayN . Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Medica Okayama2001;55(6):357‐62. [DOI: 10.18926/AMO/31997; PUBMED: 11779098] ">Akisu 2001</a>). In only one study was it explicit that infants who had received erythrocyte transfusions prior to study entry were excluded (<a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a>). For transfusion guidelines, see Additional Table (<a href="#CD004868-tbl-0002">Table 1</a>: <i>Transfusion Guidelines</i>). </p> </section> <section id="CD004868-sec-0052"> <h4 class="title">Excluded studies</h4> <p>One study (<a href="./references#CD004868-bbs2-0040" title="BiererR , RoohiM , OhlsRK . A randomized, masked study of weekly erythropoietin dosing in neonates. Pediatric Academic Societies' Annual Meeting. 2008:E‐PAS2008:633749.3. OhlsRK , ChristensenRD . Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity. Journal of Pediatrics1991;119(5):781‐8. ">Ohls 1991</a>) was excluded as it compared an EPO‐treated group with a group receiving blood transfusions. Two studies (<a href="./references#CD004868-bbs2-0037" title="MesserJ , HaddadJ , DonatoL , AstrucD , MatisJ . Early treatment of premature infants with recombinant human erythropoietin. Pediatrics1993;92(4):519‐23. [PUBMED: 8414820] ">Messer 1993</a>; <a href="./references#CD004868-bbs2-0044" title="TestaM , RealiA , CopulaM , PinnaB , BirocchiF , PisuC , et al. Role of rHuEpo on blood transfusions in preterm infants after the fifteenth day of life. Pediatric Hematology and Oncology1998;15(5):415‐20. [PUBMED: 9783307] ">Testa 1998</a>) were excluded as they were not randomised controlled trials. Two studies reported only as abstracts were excluded as one study from Saudi Arabia lacked information to ascertain whether the study was a randomised controlled trial or not (<a href="./references#CD004868-bbs2-0034" title="AminAA , AlzahraniDM . Efficacy of erythropoietin in premature infants. Pediatric Research2003;54(4):557. [PUBMED: 11938417] ">Amin 2004</a>) and the other study conducted in Iran did not provide the age of the infants at the time of enrolment (<a href="./references#CD004868-bbs2-0033" title="Ahmadpour KachoM , Zahed PashaYA , EsmailiMR , HajianK , MoradiSH . The effect of human recombinant erythropoietin on prevention of anemia of prematurity. Pediatric Research2003;54(4):564. ">Ahmadpour Kacho 2004</a>). We were unable to contact the authors for additional information. <a href="./references#CD004868-bbs2-0045" title="WarwoodTL , OhlsRK , WiedmeierSE , LambertDK , JonesC , ScoffieldSH , et al. Single‐dose darbepoetin administration to anemic preterm neonates. Journal of Perinatology2005;25(11):725‐30. [DOI: 10.1038/sj.jp.7211387; PUBMED: 16151471] ">Warwood 2005</a> was a dose‐finding study of darbepoetin (longer‐acting and more potent than EPO). Infants were randomised to receive either one or four microgram/kg of a single dose of darbepoetin, without an untreated control group. <a href="./references#CD004868-bbs2-0038" title="MeyerMP , HaworthC , MeyerJH , CommerfordA . A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. Journal of Pediatrics1996;129(2):258‐63. [PUBMED: 8765624] ">Meyer 1996</a>, <a href="./references#CD004868-bbs2-0036" title="BechensteenAG , HågåP , HalvorsenS , LiestølK , LindemannR , WhitelawA , et al. Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infants on high protein and iron intake. European Journal of Pediatrics1997;156(1):56‐61. [PUBMED: 9007493] ">Bechensteen 1997</a> and <a href="./references#CD004868-bbs2-0043" title="PathakA , RothP , PiscitelliJ , JohnsonL . Effects of vitamin E supplementation during erythropoietin treatment of the anemia of prematurity. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(4):F324‐8. [PUBMED: 12819167] ">Pathak 2003</a> lacked an untreated control group. There were no outcomes of interest in the study by <a href="./references#CD004868-bbs2-0047" title="WidnessJA , SerfassRE , HaidenN , NelsonSE , LombardKA , PollakA . Erythrocyte iron incorporation but not absorption is increased by intravenous iron administration in erythropoietin‐treated premature infants. Journal of Nutrition2006;136(7):1868‐73. [DOI: 10.1093/jn/136.7.1868; PUBMED: 16772451] ">Widness 2006</a>. In the searches in February 2010, we identified two additional studies (<a href="./references#CD004868-bbs2-0035" title="BadieeZ , PourmirzaieeMA , KelishadiR , NaseriF . Recombinant human erythropoietin and blood transfusion in low‐birth weight preterm infants under restrictive transfusion guidelines. Saudi Medical Journal2006;27(6):817‐20. [PUBMED: 16758042] ">Badiee 2006</a>; <a href="./references#CD004868-bbs2-0042" title="PashaYZ , Ahmadpour‐KachoM , HajiahmadiM , HosseiniMB . Enteral erythropoietin increases plasma erythropoietin level in preterm infants: a randomized controlled trial. Indian Pediatrics2008;45(1):25‐8. [PUBMED: 18250501] ">Pasha 2008</a>). However, as they did not report on any of our prespecified outcomes we excluded them. In the search conducted in 2012, we identified and excluded three additional studies. In <a href="./references#CD004868-bbs2-0039" title="MohammadzadehA , NaseriF . Effect of high versus low doses of human recombinant erythropoietin on the anemia of prematurity. Acta Medica Iranica2005;43(2):95‐8. ">Mohammadzadeh 2005</a>, both groups received EPO. <a href="./references#CD004868-bbs2-0046" title="WarwoodTL , LambertDK , HenryE , ChristensenRD . Very low birth weight infants qualifying for a 'late' erythrocyte transfusion: does giving darbepoetin along with the transfusion counteract the transfusion's erythropoietic suppression?. Journal of Perinatology2011;31(Suppl 1):S17‐21. ">Warwood 2011</a> reported that "only one of the 20 study subjects qualified for and received a subsequent rbc transfusion during the hospitalisation". The authors did not state if the infant who received the transfusion belonged to the darbepoetin or the control group. <a href="./references#CD004868-bbs2-0041" title="BiererR , RoohiM , OhlsRK . A randomized, masked study of weekly erythropoietin dosing in neonates. Pediatric Academic Societies' Annual Meeting. 2008:E‐PAS2008:633749.3. OhlsRK , RoohiM , PecenyHM , SchraderR , BiererR . A randomized, masked study of weekly erythropoietin dosing in preterm infants. Journal of Pediatrics2012;160(5):790‐5. [DOI: 10.1016/j.jpeds.2011.10.026; PUBMED: 22137666] ">Ohls 2012</a> compared two dosing schedules; once a week versus three times a week of EPO in infants aged seven days or more. </p> </section> </section> <section id="CD004868-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>The assessment of individual studies is presented in the table '<a href="./references#CD004868-sec-0118" title="">Characteristics of included studies</a>' and summarised in the 'Risk of Bias' graph (<a href="#CD004868-fig-0002">Figure 2</a>) and in the 'Risk of bias' summary (<a href="#CD004868-fig-0003">Figure 3</a>). All studies were reported as randomised controlled trials. Information on which to base our judgements on whether a study used concealed allocation or not was often not clearly reported. In general, the studies were of small sample size, ranging from eight (<a href="./references#CD004868-bbs2-0028" title="ShannonKM , MentzerWC , AbelsRI , WertzM , Thayer‐MoriyamaJ , LiWY , et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. Journal of Pediatrics1992;120(4 Pt 1):586‐92. ">Shannon 1992</a>) to 230 infants (<a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a>). The studies often lacked a sample size calculation. </p> <div class="figure" id="CD004868-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004868-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004868-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004868-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We performed two post hoc secondary analyses for the primary outcome 'Use of one or more red blood cell transfusions'. In the first, we compared those studies that used concealed allocation (a placebo or sham‐injection to blind the intervention) and in which there was blinding of outcome measure assessment to those studies in which this was not evident from the published report. In the second post hoc analysis, we compared the studies that used well defined criteria for red blood cell transfusions with those that used no or less well defined criteria. </p> <p><i><b>Random sequence generation</b> </i> </p> <p>There was low risk of bias in seven studies (22% of the studies; <a href="./references#CD004868-bbs2-0020" title="MeyerMP , HaworthC , McNeillL . Is the use of recombinant human erythropoietin in anemia of prematurity cost‐effective?. South African Medical Journal1996;86(3):251‐3. [PUBMED: 8658295] MeyerMP , MeyerJH , CommerfordA , HannFM , SiveAA , MollerG , et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double‐blind, placebo‐controlled study. Pediatrics1994;93(6 Pt 1):918‐23. [PUBMED: 8190577] ">Meyer 1994</a>; <a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>; <a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a>; <a href="./references#CD004868-bbs2-0030" title="WhitehallJS , PatoleSK , CampbellP . Recombinant human erythropoietin in anemia of prematurity. Indian Pediatrics1999;36(1):17‐27. [PUBMED: 10709119] ">Whitehall 1999</a>; <a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a>; <a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a>; <a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a> ). In the remaining 78% of the studies, there was an unclear risk of bias. </p> <section id="CD004868-sec-0054"> <h4 class="title">Allocation</h4> <p>We considered the concealment of allocation to be appropriate in nine studies (28% of the studies; <a href="./references#CD004868-bbs2-0006" title="BechensteenAG , HagaP , HalvorsenS , WhitelawA , LiestolK , LindemannR , et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Archieves of Disease in Childhood1993;69(1 Spec No):19‐23. [PUBMED: 8346946] BechensteenAG , HalvorsenS , HagaP . Erythropoiesis during rapid growth. Role of erythropoietin and nutrition. Annals of the New York Academy of Sciences1994;718:339‐40. [PUBMED: 8185241] BechensteenAG , HalvorsenS , HagaP , CotesPM , LiestolK . Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatrica1996;85(4):490‐5. [PUBMED: 8346946] BechensteenAG , RefsumHE , HalvorsenS , HagaP , LiestolK . Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants. Pediatric Research1995;38(5):729‐32. [DOI: 10.1203/00006450‐199511000‐00016; PUBMED: 8552441] ">Bechensteen 1993</a>; <a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>; <a href="./references#CD004868-bbs2-0002" title="Al‐KharfyT , SmythJA , WadsworthL , KrystalG , FitzgeraldC , DavisJ , et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics1996;129(1):89‐96. [PUBMED: 8757567] SmythJA , AinsworthL , KrystalG , WadsworthL . Effect of erythropoietin therapy on oxygen dependency in premature infants. Pediatric Research2002;51(3):330 A. ">Al‐Kharfy 1996</a>; <a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a>; <a href="./references#CD004868-bbs2-0030" title="WhitehallJS , PatoleSK , CampbellP . Recombinant human erythropoietin in anemia of prematurity. Indian Pediatrics1999;36(1):17‐27. [PUBMED: 10709119] ">Whitehall 1999</a>; <a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a>; <a href="./references#CD004868-bbs2-0021" title="KasperDC , WidnessJA , HaidenN , Berger A. HaydeM , PollakA , et al. Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram. Neonatology2009;95(2):164‐71. [PUBMED: 18776731] PollakA , HaydeM , HaynM , HerknerK , LombardKA , LubecG , et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin‐treated premature infants. Pediatrics2001;107(1):78‐85. [PUBMED: 11134438] ">Pollak 2001</a>; <a href="./references#CD004868-bbs2-0019" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [PUBMED: 12091844] ">Maier 2002</a>; <a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a>). In the remaining 23 studies (72% of the studies), there was an unclear risk of bias. </p> </section> <section id="CD004868-sec-0055"> <h4 class="title">Blinding</h4> <p>We considered there to be a low risk of performance bias and detection bias in 15 studies (47% of the studies; <a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a>; <a href="./references#CD004868-bbs2-0028" title="ShannonKM , MentzerWC , AbelsRI , WertzM , Thayer‐MoriyamaJ , LiWY , et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. Journal of Pediatrics1992;120(4 Pt 1):586‐92. ">Shannon 1992</a>; <a href="./references#CD004868-bbs2-0011" title="EmmersonAJ , ColesHJ , SternCM , PearsonTC . Double blind trial of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood1993;68(3 Spec No):291‐6. [PUBMED: 8466265] ">Emmerson 1993</a>; <a href="./references#CD004868-bbs2-0020" title="MeyerMP , HaworthC , McNeillL . Is the use of recombinant human erythropoietin in anemia of prematurity cost‐effective?. South African Medical Journal1996;86(3):251‐3. [PUBMED: 8658295] MeyerMP , MeyerJH , CommerfordA , HannFM , SiveAA , MollerG , et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double‐blind, placebo‐controlled study. Pediatrics1994;93(6 Pt 1):918‐23. [PUBMED: 8190577] ">Meyer 1994</a>; <a href="./references#CD004868-bbs2-0025" title="RonnestadA , MoePJ , BreivikN . Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anaemia of prematurity. Acta Paediatrica1995;84(7):809‐11. [PUBMED: 7549303] ">Ronnestad 1995</a>; <a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>; <a href="./references#CD004868-bbs2-0002" title="Al‐KharfyT , SmythJA , WadsworthL , KrystalG , FitzgeraldC , DavisJ , et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics1996;129(1):89‐96. [PUBMED: 8757567] SmythJA , AinsworthL , KrystalG , WadsworthL . Effect of erythropoietin therapy on oxygen dependency in premature infants. Pediatric Research2002;51(3):330 A. ">Al‐Kharfy 1996</a>; <a href="./references#CD004868-bbs2-0010" title="DonatoH , RendoP , VivasR , SchvartzmanG , DigregorioJ , VainN . Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double‐blind, placebo‐controlled trial comparing three different doses. International Journal of Pediatric Hematology/Oncology1996;3:279‐85. ">Donato 1996</a>; <a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a>; <a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a>; <a href="./references#CD004868-bbs2-0018" title="KumarP , ShankaranS , KrishnanRG . Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double‐blind, placebo‐controlled trial. Journal of Perinatology1998;18(3):173‐7. [PUBMED: 9659643] ">Kumar 1998</a>; <a href="./references#CD004868-bbs2-0019" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [PUBMED: 12091844] ">Maier 2002</a>; <a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a>; <a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a>; <a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a>). Many studies did not use a placebo or sham injection, precluding blinding of the intervention and the outcome measure assessment. There was a high risk of bias in 16 studies (50% of the studies; <a href="./references#CD004868-bbs2-0006" title="BechensteenAG , HagaP , HalvorsenS , WhitelawA , LiestolK , LindemannR , et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Archieves of Disease in Childhood1993;69(1 Spec No):19‐23. [PUBMED: 8346946] BechensteenAG , HalvorsenS , HagaP . Erythropoiesis during rapid growth. Role of erythropoietin and nutrition. Annals of the New York Academy of Sciences1994;718:339‐40. [PUBMED: 8185241] BechensteenAG , HalvorsenS , HagaP , CotesPM , LiestolK . Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatrica1996;85(4):490‐5. [PUBMED: 8346946] BechensteenAG , RefsumHE , HalvorsenS , HagaP , LiestolK . Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants. Pediatric Research1995;38(5):729‐32. [DOI: 10.1203/00006450‐199511000‐00016; PUBMED: 8552441] ">Bechensteen 1993</a>; <a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a>; <a href="./references#CD004868-bbs2-0004" title="BaderD , BlondheimO , JonasR , AdmoniO , Abend‐WingeM , ReichD , et al. Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity. Acta Paediatrica1996;85(4):496‐501. [PUBMED: 8740313] ">Bader 1996</a>; <a href="./references#CD004868-bbs2-0015" title="Javier ManchonG , Natal PujolA , Coroleu LletgetW , Zuasnabar CotroA , Badia BarnusellJ , Junca PieraJ , et al. Randomized multi‐centre trial of the administration of erythropoietin in anemia of prematurity [Estudio multicentrico aleatorizado de administracion de eritropoyetina en la anemia de la prematuridad]. Anales Espanoles de Pediatria1997;46(6):587‐92. [PUBMED: 9297428] ">Javier Manchon 1997</a>; <a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a>; <a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a>; <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a>; <a href="./references#CD004868-bbs2-0017" title="KivivuoriSM , VirtanenM , RaivioKO , ViinikkaL , SiimesMA . Oral iron is sufficient for erythropoietin treatment of very low birth‐weight infants. European Journal of Pediatrics1999;158(2):147‐51. [PUBMED: 10048613] ">Kivivuori 1999</a>; <a href="./references#CD004868-bbs2-0030" title="WhitehallJS , PatoleSK , CampbellP . Recombinant human erythropoietin in anemia of prematurity. Indian Pediatrics1999;36(1):17‐27. [PUBMED: 10709119] ">Whitehall 1999</a>; <a href="./references#CD004868-bbs2-0031" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm. Acta Neonatologica Japonica1999;35(4):755‐61. ">Yamada 1999a</a>; <a href="./references#CD004868-bbs2-0032" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm. Acta Neonatologica Japonica1999;35(4):762‐7. ">Yamada 1999b</a>; <a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a><a href="./references#CD004868-bbs2-0001" title="AkisuM , TuzunS , ArslanogluS , YalazM , KultursayN . Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Medica Okayama2001;55(6):357‐62. [DOI: 10.18926/AMO/31997; PUBMED: 11779098] ">Akisu 2001</a>; <a href="./references#CD004868-bbs2-0021" title="KasperDC , WidnessJA , HaidenN , Berger A. HaydeM , PollakA , et al. Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram. Neonatology2009;95(2):164‐71. [PUBMED: 18776731] PollakA , HaydeM , HaynM , HerknerK , LombardKA , LubecG , et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin‐treated premature infants. Pediatrics2001;107(1):78‐85. [PUBMED: 11134438] ">Pollak 2001</a>; <a href="./references#CD004868-bbs2-0023" title="RochaVL , BenjaminAC , ProcianoyRS . The effect of recombinant human erythropoietin on the treatment of anemia of prematurity. Journal de Pediatria2001;77(2):75‐83. [PUBMED: 14647595] ">Rocha 2001</a>; <a href="./references#CD004868-bbs2-0022" title="ReiterPD , RosenbergAA , ValuckR , NovakK . Effect of short‐term erythropoietin therapy in anemic premature infants. Journal of Perinatology2005;25(2):125‐9. [PUBMED: 15526012] ">Reiter 2005</a>). In one study (3% of the studies; <a href="./references#CD004868-bbs2-0003" title="AtasayB , GunlemezA , AkarN , ArsanS . Does early erythropoietin therapy decrease transfusions in anemia of prematurity?. Indian Journal of Pediatrics2002;69(5):389‐91. [PUBMED: 12061670] ">Atasay 2002</a>), there was an unclear risk of bias. </p> </section> <section id="CD004868-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>There was a low risk of bias for 30 studies (94% of the studies) and a high risk of bias in two studies (6% of the studies; <a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a>; <a href="./references#CD004868-bbs2-0017" title="KivivuoriSM , VirtanenM , RaivioKO , ViinikkaL , SiimesMA . Oral iron is sufficient for erythropoietin treatment of very low birth‐weight infants. European Journal of Pediatrics1999;158(2):147‐51. [PUBMED: 10048613] ">Kivivuori 1999</a>). </p> </section> <section id="CD004868-sec-0057"> <h4 class="title">Selective reporting</h4> <p>The risk of bias was unclear to us for all the studies (100%) as the study protocols were not available for us to read. </p> </section> <section id="CD004868-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>We had serious concerns about possible 'other bias' in one study (<a href="./references#CD004868-bbs2-0023" title="RochaVL , BenjaminAC , ProcianoyRS . The effect of recombinant human erythropoietin on the treatment of anemia of prematurity. Journal de Pediatria2001;77(2):75‐83. [PUBMED: 14647595] ">Rocha 2001</a>). The study <a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a> was reported in a 'Research letter' format allowing only few details. We obtained information from the Editorial office of the European Journal of Pediatrics, that 'Research letters' are peer‐reviewed. For details regarding these two studies, please see the notes under <a href="./references#CD004868-sec-0118" title="">Characteristics of included studies</a>. </p> </section> </section> <section id="CD004868-sec-0059"> <h3 class="title" id="CD004868-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD004868-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>For this update, one new study was identified (<a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a>). This added 60 infants to the review. The review now includes 31 studies (32 comparisons) that randomised 1651 infants. For details of results, see <a href="./references#CD004868-sec-0099" title="">Data and analyses</a>. </p> <p>All studies compared late initiation of erythropoietin (EPO) (8 ‐ 28 days) versus placebo or no intervention. </p> <section id="CD004868-sec-0060"> <h4 class="title">Primary Outcome:</h4> <section id="CD004868-sec-0061"> <h5 class="title">The use of one or more red blood cell transfusions (Outcome 1.1)</h5> <p>See <a href="#CD004868-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD004868-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO)." data-id="CD004868-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO). </p> </div> </div> </div> <p>A total of 21 studies including 1202 infants reported on the use of one or more red blood cell transfusions following the use of either low or high dose of EPO. There was a significant reduction in the use of one or more red blood cell transfusions (typical risk ratio (RR) 0.72, 95% confidence interval (CI) 0.65 to 0.79; typical risk difference (RD); ‐0.17, 95% CI ‐0.22 to ‐0.12; number needed to treat for an additional beneficial outcome (NNTB); 6, 95% CI 5 to 8). There was moderate heterogeneity for this outcome (for RR; I² = 66.0%; for RD; I² = 58.0%). The quality of the evidence was very low. </p> <section id="CD004868-sec-0062"> <h6 class="title">Subgroup analyses:</h6> <p>We conducted further analyses including studies that used a <b>high dose of EPO</b> (&gt; 500 IU/kg/week) or a <b>low dose of EPO</b> (≤ 500 IU/kg/week). </p> </section> </section> <section id="CD004868-sec-0063"> <h5 class="title">High dose of EPO (Outcome 1.2)</h5> <p>The summary estimates for 15 studies including 972 infants testing a <b>high dose of EPO (Outcome 1.2)</b> were statistically significant with a typical RR of 0.77 (95% CI 0.68 to 0.86), a typical RD of ‐0.14 (95% CI ‐0.19 to ‐0.08) and a NNTB of 7 (95% CI 5 to 13). There was moderate heterogeneity for this outcome for RR (I² = 63%) and for RD (I² = 62%). </p> <p>We conducted a subgroup analysis for <b>high dose of EPO in combination with high dose of iron (Outcome 1.2.1)</b>. Six studies (n = 318) showed a typical RR of 0.74 (95% CI 0.62 to 0.88), a typical RD of ‐0.16 (95% CI ‐0.24 to ‐0.08) and NNTB of 6 (95% CI 4 to 13). There was high heterogeneity for both RR (I² = 79%) and for RD (I² = 78%). </p> <p>Nine studies of <b>high EPO and low dose of iron (Outcome 1.2.2)</b> (n = 654) showed a typical RR of 0.78 (95% CI 0.67 to 0.90), a typical RD of ‐0.13 (95% CI ‐0.20 to ‐0.06) and NNTB of 8 (95% CI 5 to 20). There was moderate heterogeneity for RR (I² = 52%) and low heterogeneity for RD (I² = 29%). </p> </section> <section id="CD004868-sec-0064"> <h5 class="title">Low dose of EPO (Outcome 1.3)</h5> <p>The summary estimates for seven studies including 239 infants testing a <b>low dose of EPO (Outcome 1.3)</b> were statistically significant with a typical RR of 0.53 (95% CI 0.42 to 0.67), a typical RD of ‐0.34 (95% CI ‐0.45 to ‐0.23) and a NNTB of 3 (95% CI 2 to 4). There was moderate heterogeneity for RR (I² = 59%) and no heterogeneity for RD (I² = 14%). </p> <p>We conducted a subgroup analysis for <b>low dose of EPO in combination with high dose of iron (Outcome 1.3.1)</b>. Three studies (n = 77) showed a typical RR of 0.50 (95% CI 0.31 to 0.79), a typical RD of ‐0.31 (95% CI ‐0.49 to ‐0.13) and a NNTB of 3 (95% CI 2 to 8). There was no significant heterogeneity for this outcome for RR (I² = 0%) and RD (I² = 0%). </p> <p>Four studies (n = 162) evaluated the effectiveness of <b>low dose of EPO in combination with low dose of iron (Outcome 1.3.2)</b>. The typical RR was 0.54 (95% CI 0.41 to 0.71), the typical RD was ‐0.36 (95% CI ‐0.49 to ‐ 0.22) and the NNTB was 3 (95% CI 2 to 5). There was high heterogeneity (I² = 76%) for RR and moderate heterogeneity for RD (I² = 53%). </p> </section> </section> <section id="CD004868-sec-0065"> <h4 class="title">Secondary outcomes:</h4> <section id="CD004868-sec-0066"> <h5 class="title">The total volume (mL/kg) of blood transfused per infant (Outcome 1.4)</h5> <p>Five studies including 197 infants reported on the total volume of blood transfused per infant. The typical mean difference (MD) between the groups was not statistically significant, with a typical MD of ‐1.61 mL/kg (95% CI ‐5.78 to 2.57) transfused per infant. There was high heterogeneity (I² = 92%). The very high heterogeneity may indicate that the data are skewed and it brings uncertainty to the estimate. <a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a> (n = 60) reported on this outcome but provided only the means with no standard deviation (SD). In the two EPO groups combined, the mean was 20 mL/kg and in the control group it was 32 mL/kg (P &lt; 0.01, according to the authors). </p> </section> <section id="CD004868-sec-0067"> <h5 class="title">Number of red blood cell transfusions per infant (Outcome 1.5)</h5> <p>The number of red blood cell transfusions per infant was reported in 11 studies enrolling 817 infants. The significant typical MD was ‐0.22 (95% CI ‐0.38 to ‐0.06) favouring the EPO group. There was high heterogeneity (I² = 94%). In <a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a> (n = 42), the median number of blood transfusions was lower for the infants in the EPO group (difference in medians ‐2 (95% CI ‐4 to 0)). </p> </section> <section id="CD004868-sec-0068"> <h5 class="title">Number of donors to whom the infant was exposed (Outcome 1.6)</h5> <p>Two studies reported on donor exposure in 165 enrolled infants. The significant MD was 0.45 (95% CI 0.20 to 0.69) indicating a higher donor exposure number in the EPO group. There was high heterogeneity for this outcome (I² = 93%). </p> </section> <section id="CD004868-sec-0069"> <h5 class="title">Mortality during initial hospital stay (all causes of mortality) (Outcome 1.7)</h5> <p>Thirteen studies (14 comparisons) including 767 infants reported on mortality during initial hospital stay. The non‐significant typical RR was 0.82 (95% CI 0.49 to 1.39) and the typical RD was ‐0.01 (95% CI ‐0.05 to 0.02). There was no statistically significant heterogeneity for this outcome for either RR (I² = 0%) or RD (I² = 0%). The quality of the evidence was moderate. </p> </section> <section id="CD004868-sec-0070"> <h5 class="title">Retinopathy of prematurity (ROP) (all stages or stage not reported) (Outcome 1.8)</h5> <p>Three studies including 404 infants reported on ROP (all stages), with a non‐significant typical RR 1.27 (95% CI 0.99 to 1.64) and a typical RD of 0.09 (95% CI ‐0.00 to 0.18). There was high heterogeneity for this outcome for both RR (I² = 83%) and RD (I² = 82%). The quality of the evidence was very low. </p> </section> <section id="CD004868-sec-0071"> <h5 class="title">Retinopathy of prematurity (ROP) stage ≥ 3 (Outcome 1.9)</h5> <p>Three trials enrolling 442 infants reported on severe ROP (stage ≥ 3). The typical RR was 1.73 (95% CI 0.92 to 3.24) and the typical RD was 0.05 (95% CI ‐0.01 to 0.10); neither was statistically significant. There was unimportant heterogeneity for this outcome for RR (I² = 18%) but high heterogeneity for RD (I² = 79%). The quality of the evidence was very low. </p> </section> <section id="CD004868-sec-0072"> <h5 class="title">Proven sepsis (clinical symptoms and signs of sepsis and positive blood culture) (Outcome 1.10) </h5> <p>Five studies including 551 infants reported on this outcome. The typical RR was 0.75 (95% CI 0.52 to 1.09) and the typical RD was ‐0.05 (95% CI ‐0.11 to 0.01), neither statistically significant. There was no heterogeneity for this outcome for either RR (I² = 0%) or RD (I² = 0%). </p> </section> <section id="CD004868-sec-0073"> <h5 class="title">Necrotising enterocolitis (NEC) (Bell's stage II or higher) (Outcome 1.11)</h5> <p>Six studies including 656 infants reported on NEC. In some studies, the stage was not reported but the results were included in the meta‐analyses. The typical RR was 0.88 (95% CI 0.45 to 1.70) and the typical RD ‐0.01 (95% CI ‐0.04 to 0.02).Neither estimate was statistically significant. There was no heterogeneity for this outcome for either RR (I² = 0%) or RD (I² = 0%). The quality of the evidence was moderate. </p> </section> <section id="CD004868-sec-0074"> <h5 class="title">Intraventricular haemorrhage (IVH); all grades (Outcome 1.12)</h5> <p>Four studies including 454 infants reported on intraventricular haemorrhage (all grades). In <a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a>, there were no events in either group and that study was therefore disregarded for the RR. The non‐significant typical RR was 0.87 (95% CI 0.53 to 1.42) and typical RD was ‐0.02 (95% CI ‐0.07 to 0.04). There was no heterogeneity for either RR (I² = 0%) or RD (I² = 0%). IVH was probably not a relevant outcome in this review as most haemorrhages occur during the first few days of life and infants were enrolled later in these studies. </p> </section> <section id="CD004868-sec-0075"> <h5 class="title">Periventricular leukomalacia (PVL); cystic changes in the periventricular areas (Outcome 1.13) </h5> <p>One study enrolling 145 infants reported on PVL. The non‐significant RR was 4.80 (95% CI 0.57 to 40.05) and the RD was 0.05 (95% CI ‐0.01 to 0.12). The test for heterogeneity was not applicable. </p> </section> <section id="CD004868-sec-0076"> <h5 class="title">Bronchopulmonary dysplasia (BPD) (supplemental oxygen at 28 days of age)(Outcome 1.14)</h5> <p>Two studies (n = 285) reported on BPD at 28 days. In <a href="./references#CD004868-bbs2-0002" title="Al‐KharfyT , SmythJA , WadsworthL , KrystalG , FitzgeraldC , DavisJ , et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics1996;129(1):89‐96. [PUBMED: 8757567] SmythJA , AinsworthL , KrystalG , WadsworthL . Effect of erythropoietin therapy on oxygen dependency in premature infants. Pediatric Research2002;51(3):330 A. ">Al‐Kharfy 1996</a>, all infants in both groups had BPD. The typical RR was 1.25 (95% CI; 1.00 to 1.55) and the RD was 0.10 (95% CI 0.00 to 0.20). There was very high heterogeneity for both RR (I² = 97%) and RD (I² = 88%). Both results were of borderline statistical significance (test for overall effect: Z = 1.99 (P = 0.05)). The extremely high heterogeneity for this analysis may relate to the fact that in one study all the infants had BPD at 28 days of age. The results should be interpreted with caution. </p> </section> <section id="CD004868-sec-0077"> <h5 class="title">Bronchopulmonary dysplasia (BPD) (supplemental oxygen at 36 weeks' postmenstrual age (PMA)) (Outcome 1.15) </h5> <p>Three studies enrolling 216 infants reported on the use of supplemental oxygen at 36 weeks' PMA. The typical RR was 0.89 (95% CI 0.59 to 1.35) and the typical RD was ‐0.03 (95% CI‐0.15 to 0.08); neither was statistically significant. There was moderate heterogeneity for RR (I² = 56%) and for RD (I² = 59%). </p> </section> <section id="CD004868-sec-0078"> <h5 class="title">Sudden infant death (SIDS) after discharge (Outcome 1.16)</h5> <p>Six studies including 363 infants reported on SIDS. The typical RR was 1.06 (95% CI 0.25 to 4.52) and the typical RD was 0.00 (95% CI ‐0.03 to 0.04). Neither was statistically significant. There was no heterogeneity for either RR (I² = 0%) or RD (I² = 0%). </p> </section> <section id="CD004868-sec-0079"> <h5 class="title">Neutropenia (Outcome 1.17)</h5> <p>Five studies (six comparisons) enrolling 164 infants reported on neutropenia. The typical RR was 0.28 (95% CI 0.05 to 1.54) (in only two studies did the outcome of interest occur), and the typical RD was ‐0.04 (‐0.11 to 0.03); neither was statistically significant. There was no heterogeneity for RR (I² = 0%) and for RD (I² = 0%). </p> </section> <section id="CD004868-sec-0080"> <h5 class="title">Hypertension (Outcome 1.18)</h5> <p>Seven studies including 361 infants reported on hypertension. The RR was 1.20 (95% CI 0.46 to 3.14) and the RD 0.01 (95% CI ‐0.04 to 0.05); neither was statistically significant. There was no statistically significant heterogeneity for either RR (I² = 21%) or RD (I² = 0%). </p> </section> <section id="CD004868-sec-0081"> <h5 class="title">Length of hospital stay (days) (Outcome 1.19)</h5> <p>Length of hospital stay was reported in two studies enrolling 55 infants. There was no significant difference between the groups with a typical MD of ‐0.35 days (95% CI ‐12.83 to 12.13). There was no heterogeneity (I² = 0%). </p> </section> <section id="CD004868-sec-0082"> <h5 class="title">Long‐term outcomes assessed at any age beyond one year of age by a validated cognitive, motor, language, or behavioural/school/social interaction/adaptation test </h5> <p>Long‐term neurodevelopmental outcomes were not reported in any study.</p> </section> <section id="CD004868-sec-0083"> <h5 class="title">Any side effects reported in the trials</h5> <p>There were no serious side effects reported in most of the trials that specifically reported on adverse events (<a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a>; <a href="./references#CD004868-bbs2-0028" title="ShannonKM , MentzerWC , AbelsRI , WertzM , Thayer‐MoriyamaJ , LiWY , et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. Journal of Pediatrics1992;120(4 Pt 1):586‐92. ">Shannon 1992</a>; <a href="./references#CD004868-bbs2-0006" title="BechensteenAG , HagaP , HalvorsenS , WhitelawA , LiestolK , LindemannR , et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Archieves of Disease in Childhood1993;69(1 Spec No):19‐23. [PUBMED: 8346946] BechensteenAG , HalvorsenS , HagaP . Erythropoiesis during rapid growth. Role of erythropoietin and nutrition. Annals of the New York Academy of Sciences1994;718:339‐40. [PUBMED: 8185241] BechensteenAG , HalvorsenS , HagaP , CotesPM , LiestolK . Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatrica1996;85(4):490‐5. [PUBMED: 8346946] BechensteenAG , RefsumHE , HalvorsenS , HagaP , LiestolK . Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants. Pediatric Research1995;38(5):729‐32. [DOI: 10.1203/00006450‐199511000‐00016; PUBMED: 8552441] ">Bechensteen 1993</a>; <a href="./references#CD004868-bbs2-0031" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm. Acta Neonatologica Japonica1999;35(4):755‐61. ">Yamada 1999a</a>; <a href="./references#CD004868-bbs2-0032" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm. Acta Neonatologica Japonica1999;35(4):762‐7. ">Yamada 1999b</a>; <a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a>; <a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>; <a href="./references#CD004868-bbs2-0004" title="BaderD , BlondheimO , JonasR , AdmoniO , Abend‐WingeM , ReichD , et al. Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity. Acta Paediatrica1996;85(4):496‐501. [PUBMED: 8740313] ">Bader 1996</a>; <a href="./references#CD004868-bbs2-0010" title="DonatoH , RendoP , VivasR , SchvartzmanG , DigregorioJ , VainN . Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double‐blind, placebo‐controlled trial comparing three different doses. International Journal of Pediatric Hematology/Oncology1996;3:279‐85. ">Donato 1996</a>; <a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a>; <a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a>; <a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a>; <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a>; <a href="./references#CD004868-bbs2-0018" title="KumarP , ShankaranS , KrishnanRG . Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double‐blind, placebo‐controlled trial. Journal of Perinatology1998;18(3):173‐7. [PUBMED: 9659643] ">Kumar 1998</a>; <a href="./references#CD004868-bbs2-0017" title="KivivuoriSM , VirtanenM , RaivioKO , ViinikkaL , SiimesMA . Oral iron is sufficient for erythropoietin treatment of very low birth‐weight infants. European Journal of Pediatrics1999;158(2):147‐51. [PUBMED: 10048613] ">Kivivuori 1999</a>; <a href="./references#CD004868-bbs2-0023" title="RochaVL , BenjaminAC , ProcianoyRS . The effect of recombinant human erythropoietin on the treatment of anemia of prematurity. Journal de Pediatria2001;77(2):75‐83. [PUBMED: 14647595] ">Rocha 2001</a>; <a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a>). <a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a> reported a total of 41 different types of adverse events, with infection (positive blood cultures), pneumonia, and patent ductus arteriosus being the most common. </p> </section> </section> <section id="CD004868-sec-0084"> <h4 class="title">Secondary (post hoc) analyses:</h4> <p>In an attempt to further explore the heterogeneity observed in the primary outcome and subgroup analyses, we performed a post hoc analysis comparing the results of studies that we judged as high quality with those that we identified as of lower quality or could not precisely define their quality because of lack of information. We also compared the results of studies that used strict criteria for red blood cell transfusions to those that used no criteria or less strict criteria. </p> <section id="CD004868-sec-0085"> <h5 class="title">Use of one or more blood transfusions (secondary analysis based on quality) (Outcome 1.20) </h5> <p>For six high‐quality studies enrolling 417 infants, the typical RR was 0.83 (95% CI 0.73 to 0.95); the typical RD was ‐0.12 (95% CI ‐0.21 to ‐0.04). For 15 studies of uncertain quality enrolling 785 infants, the typical RR was 0.63 (95% CI 0.54 to 0.73) and the typical RD was ‐0.20 (‐0.26 to ‐0.14). The summary effect size was larger in the studies of poor quality. There was low heterogeneity for the high‐quality studies (I² = 49% for RR and 47% for RD), as well as for the studies of uncertain quality which had moderate heterogeneity (I² = 71% for RR and 61% for RD). </p> </section> <section id="CD004868-sec-0086"> <h5 class="title">Use of one or more blood transfusions (secondary analysis based on criteria for red blood cell transfusions) (Outcome 1.21; Outcome 1.21.1; Outcome 1.21.2) </h5> <p>We considered 16 studies enrolling 1023 infants to have used strict (although variable) guidelines for red blood cell transfusions, and three studies enrolling 97 infants to have used no criteria or less strict criteria. We excluded two studies for which we were unable to translate the text regarding possible transfusion guidelines (<a href="./references#CD004868-bbs2-0031" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm. Acta Neonatologica Japonica1999;35(4):755‐61. ">Yamada 1999a</a>; <a href="./references#CD004868-bbs2-0032" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm. Acta Neonatologica Japonica1999;35(4):762‐7. ">Yamada 1999b</a>). For the 16 studies using strict red blood cell transfusion guidelines, the typical RR was 0.76 (95% CI 0.69 to 0.85) and the typical RD was ‐0.15 (95% CI ‐0.20 to ‐0.09); NNTB 7 (95% CI 5 to 11). There was moderate heterogeneity for RR (I² = 61%) and RD (I² = 53%). For the studies using no criteria or less strict criteria, the typical RR was 0.25 (95% CI 0.08 to 0.77) and the typical RD was ‐0.21 (95% CI ‐0.36 to ‐0.07); NNTB 5 (95% CI 3 to 14). There was no heterogeneity for the studies using no criteria or less strict criteria for RR (I² = 0%) and RD (I² = 0%). The summary effect size was larger for the studies that did not use strict guidelines for red blood cell transfusions compared to those that did. </p> </section> </section> <section id="CD004868-sec-0087"> <h4 class="title">Funnel plot</h4> <p>A funnel plot for the primary outcome 'Use of one or more red blood cell transfusions' was asymmetric, with a relative absence of smaller studies not having a protective effect (see <a href="#CD004868-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD004868-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO)." data-id="CD004868-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO). </p> </div> </div> </div> </section> <section id="CD004868-sec-0088"> <h4 class="title">Enterally‐dosed EPO</h4> <p>One study (<a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a>) using enterally‐dosed EPO found that the intervention did not significantly influence erythropoiesis or iron utilisation when given for a two‐week period, nor did it elevate the serum EPO concentration in preterm or term infants. The authors concluded that enterally‐dosed EPO is not an effective substitute for parenteral administration (<a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004868-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004868-sec-0089"></div> <section id="CD004868-sec-0090"> <h3 class="title" id="CD004868-sec-0090">Summary of main results</h3> <p>The current review included 31 studied (32 comparisons) meeting our inclusion criteria. These studies included a total of 1651 preterm or low birth weight infants and reported on at least one of the outcomes of interest for this systematic review. </p> <p>The results showed that late administration of erythropoietin reduces the use of one or more blood transfusions following study entry. These results were quite consistent (overlapping confidence intervals) when including studies that used both low and high doses of EPO in combination with low and high doses of iron. </p> <p>With the inclusion of <a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a>, in which there was a statistically significant increase in retinopathy of prematurity (ROP) at all stages and at stage 3 or higher, the overall estimates in the meta‐analyses now showed a trend towards increase for both these outcomes. Three studies including 404 infants reported on ROP (all stages), with a typical RR 1.27 (95% CI 0.99 to 1.64) and a typical RD of 0.09 (95% CI ‐0.00 to 0.18). This outcome was not statistically significantly different between the groups. There was high heterogeneity for this outcome for both RR (I² = 83%) and RD (I² = 82%). Three trials enrolling 442 infants reported on severe ROP (stage 3 or higher). The typical RR was 1.73 (95% CI 0.92 to 3.24) and the typical RD was 0.05 (95% CI ‐0.01 to 0.10); neither was statistically significant. There was minimal heterogeneity for this outcome for RR (I² = 18%) but high heterogeneity for RD (I² = 79%). As the cut‐off for early EPO treatment versus late EPO treatment was set arbitrarily at eight completed days of age of initiation of treatment, we thought it justified to include all studies that have reported on ROP in secondary analyses. Details of these analyses were presented in the 2014 update of the early EPO review (<a href="./references#CD004868-bbs2-0067" title="OhlssonA , AherSM . Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD004863.pub3] ">Ohlsson 2012</a>). We combined all studies that reported on ROP at stage 3 or higher regardless of at what age the EPO treatment was initiated. We included seven studies from the early EPO review and three studies from the late EPO review that reported on this outcome. A total of 10 studies enrolling 1303 infants reported on this outcome. There was a significantly increased risk of ROP stage 3 or higher (typical RR 1.48 (95% CI 1.02 to 2.13); typical RD 0.03 (95% CI 0.00 to 0.06) (P = 0.04 for RR and 0.03 for RD); number needed to treat for an additional harmful outcome (NNTH) 33 (95% CI 17 to infinity)). There was no heterogeneity for RR (1² = 0%) and moderate heterogeneity (I² = 50%) for RD. </p> </section> <section id="CD004868-sec-0091"> <h3 class="title" id="CD004868-sec-0091">Overall completeness and applicability of evidence</h3> <p>The number needed to treat for an additional beneficial outcome (NNTB) to avoid one red blood cell transfusion was low (range 3 to 8, for different combinations of EPO and iron). The clinical importance of this finding is lessened by the fact that any donor exposure was not avoided, as many infants required red blood cell transfusions prior to study entry. Only two studies reported on donor exposure. In the study by <a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a>, there was a statistically significant increase in the number of donors the infants were exposed to but not in the study by <a href="./references#CD004868-bbs2-0019" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [PUBMED: 12091844] ">Maier 2002</a>. In the meta analysis of the two studies, a significant difference in the typical mean difference for number of transfusions was noted indicating a higher donor exposure number in the EPO group. There was very high heterogeneity for this outcome (I² = 93%), reducing the importance of the finding. In addition, in the 2012 and 2013 updates there was no statistically significant reduction in the total volume (mL/kg) of blood transfused per infant. There was a small reduction in the mean number of transfusions (0.2) per infant. </p> <p>The need for intravenous, intramuscular, or subcutaneous injections with EPO/iron treatment in the neonatal period is associated with repeated painful stimuli and could potentially have adverse long‐term effects. This has not been addressed in any study. </p> </section> <section id="CD004868-sec-0092"> <h3 class="title" id="CD004868-sec-0092">Quality of the evidence</h3> <p>The study quality varied and important information regarding the random sequence generation and whether the allocation was concealed or not was often missing. No study was reported according to the 'Consort' statement (<a href="./references#CD004868-bbs2-0051" title="AltmanDG , MoherD , SchultzKF . Improving the reporting of randomised trials: the CONSORT statement and beyond. Statistics in Medicine2012;31(25):2985‐97. [DOI: 10.1002/sim.5402; PUBMED: 22903776] ">CONSORT 2012</a>). Sample sizes were small and long‐term outcomes (18 to 24 months corrected age) were not reported. In only one study (<a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a>), did the authors state that infants were not eligible to enter the study if they had previously received a red blood cell transfusion. Most studies followed guidelines for red blood cell transfusions, although these varied between the studies. </p> <p>For the primary outcome of 'use of one or more blood transfusions', the typical risk ratio (RR) for six high‐quality studies was 0.83 (95% CI 0.73 to 0.95). For 15 studies of uncertain quality, the typical RR was 0.63 (95% CI 0.54 to 0.73). The CIs for these analyses were not overlapping, indicating that there were statistically significant differences in the effect sizes between studies that could be ascertained as being of high quality and studies of uncertain quality. There was a reduction in heterogeneity when the high‐quality studies were analysed separately. Studies of higher quality often show lower effect sizes (<a href="./references#CD004868-bbs2-0070" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [PUBMED: 7823387] ">Schulz 1995</a>). Judging the quality of a study depends to a large extent on the information published, and obtaining additional information from the authors may change the evaluations. The typical effect size for studies that used strict red blood cell transfusion guidelines was smaller (RR 0.76) than for studies that used no or less strict criteria (RR 0.25). </p> <p>Of concern is the finding of moderate heterogeneity for the primary outcome, including all combinations of low and high EPO and low and high iron treatment. The heterogeneity remained for individual combinations of EPO and iron. The heterogeneity could possibly be explained by the fact that the studies were conducted in 22 countries, with presumably different care practices. Of note, the control rates for red blood cell transfusions varied markedly between studies. As noted in the Additional <a href="#CD004868-tbl-0002">Table 1</a>, there was large variation in the guidelines for red blood cell transfusions. The results of these post hoc analyses should therefore be interpreted with caution. </p> </section> <section id="CD004868-sec-0093"> <h3 class="title" id="CD004868-sec-0093">Potential biases in the review process</h3> <p>As outlined in Figure 5 (Funnel plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) versus placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO)), there was a paucity of smaller studies not having a protective effect. It is possible that such studies have been conducted and that the results have not been published. </p> <p>Several studies were supported by pharmaceutical companies and some authors were employed by such companies. </p> <p>We are not aware of any potential biases in our own review process.</p> </section> <section id="CD004868-sec-0094"> <h3 class="title" id="CD004868-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>Systematic reviews of the efficacy of EPO in anaemia of prematurity have been published (<a href="./references#CD004868-bbs2-0075" title="VamvakasEC , StraussRG . Meta‐analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion2001;41(3):406‐15. [PUBMED: 11274599] ">Vamvakas 2001</a>; <a href="./references#CD004868-bbs2-0056" title='GarciaMG , HutsonAD , ChrisensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a>; <a href="./references#CD004868-bbs2-0063" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). <a href="./references#CD004868-bbs2-0075" title="VamvakasEC , StraussRG . Meta‐analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion2001;41(3):406‐15. [PUBMED: 11274599] ">Vamvakas 2001</a> concluded that there is extreme variation in the results, and, until this variation is better understood, it is too early to recommend EPO as standard treatment for the anaemia of prematurity. <a href="./references#CD004868-bbs2-0056" title='GarciaMG , HutsonAD , ChrisensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a> concluded that administering EPO to VLBW neonates can result in a modest reduction in late erythrocyte transfusions and that this effect is dependent on the dose of EPO used. <a href="./references#CD004868-bbs2-0063" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a> concluded that if EPO is begun in the first week of life, a moderate reduction can be expected in the proportion of VLBW neonates transfused. The reduction was less significant for early transfusion than for late transfusion. Direct comparisons regarding the results of this systematic overview and previous reviews (<a href="./references#CD004868-bbs2-0075" title="VamvakasEC , StraussRG . Meta‐analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion2001;41(3):406‐15. [PUBMED: 11274599] ">Vamvakas 2001</a>; <a href="./references#CD004868-bbs2-0056" title='GarciaMG , HutsonAD , ChrisensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a>; <a href="./references#CD004868-bbs2-0063" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>) are not appropriate as our review included a much larger sample of studies. In 2015, the French Society of Neonatology published "Recombinant human erythropoietin in neonates: guidelines for clinical practice". The publication is labelled as a systematic evidence review. They reported that "Early EPO reduced the risk of RBC transfusions, donor exposure, and the number of transfusions in very preterm infants (LE2) (LE = level of evidence). Late EPO reduced the risk of RBC transfusions and the number of transfusions in very preterm infants (LE2). There is no difference between the effectiveness of early and late EPO (LE2). There is no difference between high‐dose and low‐dose EPO (LE2). The level of evidence is too low to recommend the intravenous route. EPO has no impact on the rate of bronchopulmonary dysplasia, necrotising enterocolitis (LE3), and retinopathy of prematurity (LE2). The level of evidence is too low to recommend EPO for neuro protection in very preterm or term infants". They concluded; "EPO to reduce RBC transfusion in very preterm infants is recommended (Level A). The optimal time to start therapy is unknown (Level B). The recommended dose is 750 IU/kg/week via three subcutaneous injections for 6 weeks (Level B)". To our knowledge, there is no other recent systematic review for late EPO (<a href="./references#CD004868-bbs2-0064" title="LopezE , BeuchéeA , TruffertP , PouvreauN , PatkaiJ , BaudO , et al. Recombinant human erythropoietin in neonates: guidelines for clinical practice from the French Society of Neonatology [L’érythropoïétine humaine recombinante chez le nouveau‐né : recommandations pour la pratique clinique de la Société française de néonatologie]. Archives de Pédiatrie2015;22(10):1092‐7. [DOI: 10.1016/j.arcped.2015.07.001; PUBMED: 26320680] ">Lopez 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004868-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update" data-id="CD004868-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004868-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004868-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO)." data-id="CD004868-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO)." data-id="CD004868-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Late initiation of EPO (8 ‐ 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 1 Use of one or more red blood cell transfusions (low and high dose of EPO)." data-id="CD004868-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 1 Use of one or more red blood cell transfusions (low and high dose of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 2 Use of one or more red blood cell transfusions (high dose of EPO)." data-id="CD004868-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 2 Use of one or more red blood cell transfusions (high dose of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 3 Use of one or more red blood cell transfusions (low dose of EPO)." data-id="CD004868-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 3 Use of one or more red blood cell transfusions (low dose of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 4 Total volume (mL/kg) of red blood cells transfused per infant." data-id="CD004868-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 4 Total volume (mL/kg) of red blood cells transfused per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 5 Number of red blood cell transfusions per infant." data-id="CD004868-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 5 Number of red blood cell transfusions per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 6 Number of donors the infant was exposed to." data-id="CD004868-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 6 Number of donors the infant was exposed to. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 7 Mortality during initial hospital stay (all causes)." data-id="CD004868-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 7 Mortality during initial hospital stay (all causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 8 Retinopathy of prematurity (all stages or stage not reported)." data-id="CD004868-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 8 Retinopathy of prematurity (all stages or stage not reported). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 9 Retinopathy of prematurity (stage ≥ 3)." data-id="CD004868-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 9 Retinopathy of prematurity (stage ≥ 3). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 10 Proven sepsis." data-id="CD004868-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 10 Proven sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 11 Necrotising Enterocolitis ≥ Bell's stage 2." data-id="CD004868-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 11 Necrotising Enterocolitis ≥ Bell's stage 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 12 Intraventricular haemorrhage all grades (or grade not specified)." data-id="CD004868-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 12 Intraventricular haemorrhage all grades (or grade not specified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 13 Periventricular leukomalacia." data-id="CD004868-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 13 Periventricular leukomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 14 Bronchopulmonary dysplasia (supplementary oxygen at 28 days)." data-id="CD004868-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 14 Bronchopulmonary dysplasia (supplementary oxygen at 28 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 15 Bronchopulmonary dysplasia (supplementary oxygen at 36 weeks' postmenstrual age)." data-id="CD004868-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 15 Bronchopulmonary dysplasia (supplementary oxygen at 36 weeks' postmenstrual age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 16 SIDS." data-id="CD004868-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 16 SIDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 17 Neutropenia." data-id="CD004868-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 17 Neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 18 Hypertension." data-id="CD004868-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 18 Hypertension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 19 Length of hospital stay (days)." data-id="CD004868-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 19 Length of hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 20 Use of one or more red blood cell transfusions (secondary analysis based on study quality)." data-id="CD004868-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 20 Use of one or more red blood cell transfusions (secondary analysis based on study quality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004868-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/urn:x-wiley:14651858:media:CD004868:CD004868-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_t/tCD004868-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 21 Use of one or more red blood cell transfusions (secondary analysis based on RBC transfusion guidelines)." data-id="CD004868-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Late initiation of EPO (8‐28 days) vs. placebo or no intervention, Outcome 21 Use of one or more red blood cell transfusions (secondary analysis based on RBC transfusion guidelines). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/media/CDSR/CD004868/image_n/nCD004868-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004868-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Late EPO compared with placebo or no intervention for complications of preterm birth ‐ primary and secondary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants</b> with low birth weight </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: Late EPO</b> </p> <p><b>Comparison: Placebo or no intervention</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>EPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of one or more red blood cell transfusions (low and high dose of EPO) during initial hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.72</b> (0.65 to 0.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1202<br/> (21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in 16 of the studies, about allocation concealment in 17 of the studies and about blinding (performance bias and detection bias) in 11 of the studies. We downgraded the quality of the evidence by one step.<br/> Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 66% and for<br/> the typical RD 58% (both moderate heterogeneity). We downgraded the quality of the evidence by one step.<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the large sample size (n = 1202), the point estimate was precise with a narrow 95% CI.<br/> Presence of publication bias: The funnel plot was asymmetrical ‐ we downgraded the quality of the evidence by one step. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>603 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>434 per 1000</b><br/> (392 to 477) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising Enterocolitis ≥ Bell's stage 2 during initial hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.88</b> </p> <p>(0.45 to 1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>656<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in two of the studies, about allocation concealment in three of the studies and about blinding (performance bias and detection bias) in one of the studies. We downgraded the quality of the evidence by one step. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for both the typical RR and for the typical RD was 0% (both no heterogeneity).<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the sample size (n = 656), the point estimate was quite precise with a narrow 95% CI.<br/> Presence of publication bias: As only six studies were included in the analyses we did not perform a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (23 to 88) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality during initial hospital stay (all causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.82</b> (0.49 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>767<br/> (14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in 11 of the studies, about allocation concealment in 7 of the studies and about blinding (performance bias and detection bias) in six of the studies. We downgraded the quality of the evidence by one step.<br/> Heterogeneity/Consistency: I<sup>2</sup> for the typical RR and for the RD was 0% (both no heterogeneity).<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the large sample size (n = 1202), the point estimate was precise with a narrow 95% CI.<br/> Presence of publication bias: The funnel plot was symmetrical. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> <p>(31 to 88)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Retinopathy of prematurity (all stages or stage not reported) during initial hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.27 (0.99 to 1.64)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>404<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in two of the studies, about allocation concealment in none of the studies, and about blinding (performance bias and detection bias) in two of the studies. We downgraded the quality of the evidence by one step.<br/> Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 83% and for the typical RD 82% (both high heterogeneity). We downgraded the quality of the evidence by one step.<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the small sample size (n = 404 ), the point estimate was not precise. We downgraded the quality of the evidence by one step.<br/> Presence of publication bias: As there was only three studies included we did not perform a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>417 per 1000</b><br/> (325 to 538) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Retinopathy of prematurity (stage ≥ 3) during initial hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.73 (0.92 to 3.24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>442<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about random sequence generation in two of the studies, about allocation concealment in none of the studies, and about blinding (performance bias and detection bias) in two of the studies. We downgraded the quality of the evidence by one step.<br/> Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 18% (no heterogeneity) and for<br/> the typical RD 79% (high heterogeneity). We downgraded the quality of the evidence by one step.<br/> Directness of evidence: Studies were conducted in the target population.<br/> Precision: Because of the small sample size (n = 442 ), the point estimate was not precise. We downgraded the quality of the evidence by one step.<br/> Presence of publication bias: As there was only three studies included we did not perform a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b><br/> (58 to 203) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>EPO</b> : erythropoietin; <b>I<sup>2</sup> </b> = I‐squared; <b>NICU</b> : Neonatal Intensive Care Unit; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004868-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Transfusion guidelines</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0001" title="AkisuM , TuzunS , ArslanogluS , YalazM , KultursayN . Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Medica Okayama2001;55(6):357‐62. [DOI: 10.18926/AMO/31997; PUBMED: 11779098] ">Akisu 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guidelines for transfusions were not presented.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0002" title="Al‐KharfyT , SmythJA , WadsworthL , KrystalG , FitzgeraldC , DavisJ , et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics1996;129(1):89‐96. [PUBMED: 8757567] SmythJA , AinsworthL , KrystalG , WadsworthL . Effect of erythropoietin therapy on oxygen dependency in premature infants. Pediatric Research2002;51(3):330 A. ">Al‐Kharfy 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The indications for transfusion were 1) shock, 2) cumulative loss of ≥ 10% of the blood volume in 72 hours or less when further blood sampling is expected, 3) Hb &lt; 130 g/L in acutely ill neonates with cardiorespiratory disease, and 4) Hb &lt; 80 to 100 g/L with clinical signs of anaemia. A volume of 15 mL/kg was recommended for each transfusion. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0003" title="AtasayB , GunlemezA , AkarN , ArsanS . Does early erythropoietin therapy decrease transfusions in anemia of prematurity?. Indian Journal of Pediatrics2002;69(5):389‐91. [PUBMED: 12061670] ">Atasay 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criteria for blood transfusion (10 mL/kg packed red cells) were as follows: a Hct &lt; 30% when signs and symptoms attributed to anaemia including persistent tachycardia (180 beats/min for 24 hours), frequent apnoea with bradycardia and daily weight gain &lt; 10 g/kg despite optimal protein and caloric intake (3.5 g/kg, 100 kcal/kg/day). Infants were transfused with a Hct of 35% to 40% if they received more than 40% oxygen or ventilation therapy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0004" title="BaderD , BlondheimO , JonasR , AdmoniO , Abend‐WingeM , ReichD , et al. Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity. Acta Paediatrica1996;85(4):496‐501. [PUBMED: 8740313] ">Bader 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criteria for blood transfusion (10 mL/kg of red cells) were as follows: a) a Hct &lt; 25%, b) an increased frequency of apnoeic events which required either stimulation or aminophylline therapy, c) changes in heart rate patterns, e.g. an increase in frequency of bradycardia (&lt; 80 beats/min) or tachycardia (&gt; 180 beats/min, d) failure of weight gain of &gt; 10 g/kg/day despite an optimal caloric intake of &gt; 120 kcal/day and e) lethargy without evidence of sepsis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0005" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoetic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [DOI: 10.4103/2249‐4847.154103] ">Basiri 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines for preterm infants included: (1) asymptomatic infants with Hct &lt; 21% and reticulocytes &lt; 2%; (2) infants with haematocrit &lt; 31% and hood O<sub>2</sub> &lt; 36% or mean airway pressure &lt; 6 cm H<sub>2</sub>O by continuous positive airway pressure (CPAP) or intermittent mandatory ventilation (IMV) or &gt; 9 apnoeic and bradycardic episodes per 12 hours or 2/24 hours requiring bag‑and‑mask ventilation while on adequate methylxanthine therapy or heart rate &gt; 18/min or respiratory rate &gt; 80/min sustained for 24 hours or weight gain of &lt; 10 g/day for 4 days on 100 kcal/kg/day or having surgery; (3) infants with haematocrit &lt; 36% and requiring &gt; 35% O<sub>2</sub> or mean airway pressure of 6 to 8 cm H<sub>2</sub>O by CPAP or IMV. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0006" title="BechensteenAG , HagaP , HalvorsenS , WhitelawA , LiestolK , LindemannR , et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Archieves of Disease in Childhood1993;69(1 Spec No):19‐23. [PUBMED: 8346946] BechensteenAG , HalvorsenS , HagaP . Erythropoiesis during rapid growth. Role of erythropoietin and nutrition. Annals of the New York Academy of Sciences1994;718:339‐40. [PUBMED: 8185241] BechensteenAG , HalvorsenS , HagaP , CotesPM , LiestolK . Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatrica1996;85(4):490‐5. [PUBMED: 8346946] BechensteenAG , RefsumHE , HalvorsenS , HagaP , LiestolK . Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants. Pediatric Research1995;38(5):729‐32. [DOI: 10.1203/00006450‐199511000‐00016; PUBMED: 8552441] ">Bechensteen 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indications of blood transfusions were: 1) Hb &lt; 80 g/L or 2) otherwise at the discretion of the clinician caring for the infant according to symptoms and signs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0007" title="BiererR , RoohiM , PecenyC , OhlsRK . Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Journal of Pediatric Surgery2009;44(8):1540‐5. [DOI: 10.1016/j.jpedsurg.2008.10.112; PUBMED: 19635302] ">Bierer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very specific transfusion criteria were in place for infants on mechanical ventilation, for infants who required supplemental oxygen and for infants on room air. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0008" title="ChenJY , WuTS , ChanlaiSP . Recombinant human erythropoietin in the treatment of anemia of prematurity. American Journal of Perinatology1995;12(5):314‐8. [DOI: 10.1055/s‐2007‐994483; PUBMED: 8540930] ">Chen 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were given because of frequent and prolonged apnoea.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0009" title="CoronaG , FuliaF , LiottaC , BarberiI . Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia [Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita]. Rivista Italiana Pediatria1998;24:442‐9. ">Corona 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were considered based on the clinical condition (pallor, tachycardia, tachypnoea, apnoea with or without bradycardia, poor weight gain, difficulties with sucking) and haematological parameters (Hb &lt; 70 g/L, Hct &lt; 26%, with low reticulocyte counts). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0010" title="DonatoH , RendoP , VivasR , SchvartzmanG , DigregorioJ , VainN . Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double‐blind, placebo‐controlled trial comparing three different doses. International Journal of Pediatric Hematology/Oncology1996;3:279‐85. ">Donato 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During the first week of life, infants were given transfusions of packed red blood cells for replacement when blood drawn for analysis was in excess of 8 mL/kg of body weight; fresh whole blood was given if signs attributable to hypovolaemia or anaemia developed. Subsequently, infants with heart rate &gt; 180 beats/min, severe apnoea/bradycardia or poor weight gain (&lt; 10 grams/day in spite of a 100 calories/day intake during 5 consecutive days) were transfused if the Hct was &lt; 25% (or &lt; 30% if oxygen or mechanical ventilation was required); asymptomatic infants were transfused only when a central Hct &lt; 23% was reached. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0011" title="EmmersonAJ , ColesHJ , SternCM , PearsonTC . Double blind trial of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood1993;68(3 Spec No):291‐6. [PUBMED: 8466265] ">Emmerson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The decision to give a blood transfusion to a study infant was made by the medical staff of the neonatal unit who were blinded to the randomisation. The unit policy at the time of the study was to transfuse a preterm infant who had a Hb &lt; 100 g/L and who had symptoms consistent with those caused by anaemia. The symptoms and signs of anaemia included poor feeding, tachycardia, tachypnoea, apnoea, and pallor. Infants with a Hb &lt; 80 g/L were transfused even if asymptomatic. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0012" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998a</a>; <a href="./references#CD004868-bbs2-0013" title="GiannakopoulouC , BolonakiI , StiakakiE , DimitriouH , GalanakiH , HatzidakiE , et al. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia. Pediatric Hematology and Oncology1998;15(1):37‐43. [PUBMED: 9509504] ">Giannakopoulou 1998b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indications for blood transfusion were a Hb &lt; 80 g/L or otherwise at the discretion of the physician treating the infants according to symptoms and signs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0014" title="GriffithsG , LallR , ChatfieldS , ShortA , MacKayP , WilliamsonP , et al. Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F190‐2. [PUBMED: 9175950] ">Griffiths 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants were transfused if they were ventilated and/or oxygen‐dependent with a Hb of &lt; 120 g/L, had clinically symptomatic anaemia, or were asymptomatic with a Hb of &lt; 70 g/L. Infants were transfused if they were ventilated and/or oxygen‐dependent with a Hb of &lt; 120 g/L, had clinically symptomatic anaemia, or were asymptomatic with a haemoglobin of &lt; 70 g/L. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0015" title="Javier ManchonG , Natal PujolA , Coroleu LletgetW , Zuasnabar CotroA , Badia BarnusellJ , Junca PieraJ , et al. Randomized multi‐centre trial of the administration of erythropoietin in anemia of prematurity [Estudio multicentrico aleatorizado de administracion de eritropoyetina en la anemia de la prematuridad]. Anales Espanoles de Pediatria1997;46(6):587‐92. [PUBMED: 9297428] ">Javier Manchon 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines were similar in all three centres (details not provided).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0016" title="JuulSE . Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. Journal of Pediatrics2003;143(3):321‐6. [PUBMED: 14517513] ">Juul 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>By NICU policy, on admission, infants weighing &lt; 1000 grams at birth were assigned 1 unit of packed red blood cells divided into 8 aliquots. These aliquots were used for transfusions during the first month of life. The following transfusion guideline was used for infants of all birth weights: Transfusion is recommended for a Hct &lt; 35% if the infant requires positive pressure with a mean airway pressure &gt; 6 cm H<sub>2</sub>O and requires &gt; 35% oxygen. Transfusion is recommended for Hct &lt; 30% if the infant requires oxygen (&lt; 35% FIO<sub>2</sub>), is receiving continuous positive airway pressure or intubated with mean airway pressure &lt; 6 cm H<sub>2</sub>O, if an infant has significant apnoea and bradycardia while receiving methylxanthines (&gt; 9 episodes in 12 hours or 2 episodes in 24 hours requiring mask‐and‐bag ventilation), if the heart rate is &gt; 180 beats/min or respiratory rate &gt; 80/min and persists for 24 hours, if weight gain &lt; 10 grams/day over 4 days despite adequate calories, or in the presence of sepsis. If the Hct is &lt; 20%, no symptoms are necessary for transfusion.<br/> Transfusion volumes were standardised as follows: infants received an initial transfusion of 15 mL/kg over a period of 3 to 4 hours. A follow‐up Hct was checked after 4 hours. If the Hct was &lt; 30%, a second aliquot of 10 mL/kg was given </p> <p>If the Hct was between 30% and 35%, an additional 5 mL/kg was given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0017" title="KivivuoriSM , VirtanenM , RaivioKO , ViinikkaL , SiimesMA . Oral iron is sufficient for erythropoietin treatment of very low birth‐weight infants. European Journal of Pediatrics1999;158(2):147‐51. [PUBMED: 10048613] ">Kivivuori 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The Hct values were maintained at &gt; 30% by red blood cell transfusions (10 mL/kg per time) in asymptomatic infants. In infants who had symptoms or signs of anaemia, red blood cells were transfused if the Hct value was &lt; 40%. The transfusion policies were the same in all study hospitals. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0018" title="KumarP , ShankaranS , KrishnanRG . Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double‐blind, placebo‐controlled trial. Journal of Perinatology1998;18(3):173‐7. [PUBMED: 9659643] ">Kumar 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The need for erythrocyte transfusion was assessed by the clinicians caring for each infant and the decision to transfuse was made without consulting the study investigators. According to the practice in the NICU, infants received transfusion if a Hct level of &lt; 27% was associated with one of the following signs and symptoms of anaemia: 1) frequent apnoea and bradycardia, defined as &gt; 6 episodes in 12 hours or any episode requiring bag‐and‐mask ventilation, in an infant with therapeutic serum levels of theophylline; 2) persistent tachycardia, defined as &gt; 180 beats/min for more than 12 hours; 3) poor weight gain (&lt; 10 grams/day averaged over a 7‐day period) despite adequate caloric intake; and 4) increasing oxygen requirement in infants with chronic lung disease despite optimum diuretic and bronchodilator therapy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0019" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [PUBMED: 12091844] ">Maier 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants with artificial ventilation or in &gt; 40% of inspired oxygen were not transfused unless Hct dropped to &lt; 40%. Spontaneously breathing infants were not transfused unless Hct dropped to &lt; 35% during the first 2 weeks of life, 30% during the 3rd to 4th weeks, and 25% thereafter. Transfusion was allowed when life‐threatening anaemia or hypovolaemia was assumed by the treating neonatologist, or surgery was planned. Twelve of the 14 centres used satellite packs of the original red cell pack to reduce donor exposure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0020" title="MeyerMP , HaworthC , McNeillL . Is the use of recombinant human erythropoietin in anemia of prematurity cost‐effective?. South African Medical Journal1996;86(3):251‐3. [PUBMED: 8658295] MeyerMP , MeyerJH , CommerfordA , HannFM , SiveAA , MollerG , et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double‐blind, placebo‐controlled study. Pediatrics1994;93(6 Pt 1):918‐23. [PUBMED: 8190577] ">Meyer 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct quote: "The need for blood transfusion was assessed by the attending neonatal physician and decisions were made independently of the investigators. The following guidelines were developed, based on existing literature and nursery practices: </p> <p><b>a</b>. Hct &lt; 30% and </p> <p>1) Weight gain of &lt; 10 grams/day averaged over 1‐week period (infant tolerating full oral feeds and receiving adequate calories). </p> <p>2) Three or more episodes of apnoea (respirations absent for 20 seconds) or bradycardia (heart rate of &lt; 100 beats per minute) in a 24‐hour period not due to other causes and not responsive to methylxanthine treatment. </p> <p>3) Tachycardia (&gt; 170 beats/min) or tachypnoea (&gt; 70 breaths/min) sustained over a 24‐hour period or associated with acute cardiac decompression. </p> <p>4) A requirement for surgery.</p> <p><b>b</b>. Development of a clinically significant patent ductus arteriosus (i.e. at least three of the following features: heart rate &gt; 160 beats/min, brisk brachial and/or dorsalis pedis pulses, palpable precordial pulsation, systolic murmur, cardiomegaly on chest radiograph). </p> <p><b>c</b>. Pulmonary disease and fractional inspired oxygen concentrations increasing by &gt; 10% per week. </p> <p><b>d</b>. Systemic infection (either clinically suspected or proven on blood culture) associated with a sudden decrease in hematocrit. </p> <p><b>e</b>. Hematocrit of 22% or less and an absolute reticulocyte count of &lt; 100 000 x 10<sup>9</sup>/L". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0021" title="KasperDC , WidnessJA , HaidenN , Berger A. HaydeM , PollakA , et al. Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram. Neonatology2009;95(2):164‐71. [PUBMED: 18776731] PollakA , HaydeM , HaynM , HerknerK , LombardKA , LubecG , et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin‐treated premature infants. Pediatrics2001;107(1):78‐85. [PUBMED: 11134438] ">Pollak 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard NICU transfusion criteria were used (authors refer to <a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a>; see below). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0022" title="ReiterPD , RosenbergAA , ValuckR , NovakK . Effect of short‐term erythropoietin therapy in anemic premature infants. Journal of Perinatology2005;25(2):125‐9. [PUBMED: 15526012] ">Reiter 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conservative transfusion guidelines were in place and followed. Criteria for red blood cell transfusion in the acutely ill infant requiring mechanical ventilation or nasal continuous positive airway pressure included: phlebotomy loss of &gt; 15% of blood volume associated with hypotension, or Hct &lt; 30%. Criteria for red blood cell transfusion in the convalescent infant requiring no more than supplemental oxygen included: Hct &lt; 28% with symptomatic anaemia (tachycardia, poor somatic growth, or metabolic acidosis) or Hct &lt; 20%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0023" title="RochaVL , BenjaminAC , ProcianoyRS . The effect of recombinant human erythropoietin on the treatment of anemia of prematurity. Journal de Pediatria2001;77(2):75‐83. [PUBMED: 14647595] ">Rocha 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The decision for blood transfusion within the whole study population was made by the assistant doctor of each newborn, and was based on the following criteria: Hct ≤ 20%, inadequate weight gain, 3 or more apnoea or bradycardia episodes within 24 hours, presurgical procedure requirement, disease associated with sudden Hct decline, restoration of the blood collected for lab exams, maintenance of Hct up to 30% associated with minimal ventilatory support requirement, and Hct up to 35% when ventilation requirements are greater. The assistant doctor who recommended blood transfusion did not know to which group the infant belonged. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0024" title="RomagnoliC , ZeccaE , GalliniF , GirlandoP , ZuppaAA . Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics2000;159(8):627‐8. [PUBMED: 10968244] ">Romagnoli 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants on mechanical ventilation and/or on more than 30% of inspired oxygen received packed erythrocytes when their Hct levels dropped below 40%. Otherwise the transfusion was performed when the Hct fell below 35% from the 2nd to the 4th week of life and below 23% thereafter. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0025" title="RonnestadA , MoePJ , BreivikN . Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anaemia of prematurity. Acta Paediatrica1995;84(7):809‐11. [PUBMED: 7549303] ">Ronnestad 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were given on the orders of the attending physician if Hb was &lt; 90 g/L or otherwise as necessary according to signs and symptoms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0026" title="SamanciN , OvaliF , DaoluT . Effects of recombinant human erythropoietin in infants with very low birth weights. Journal of International Medical Research1996;24(2):190‐8. [DOI: 10.1177/030006059602400203; PUBMED: 8737229] ">Samanci 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The need for packed erythrocyte transfusions was judged by the attending neonatologist. Guidelines for erythrocyte transfusions were developed as follows: 1) Hct of ≤ 22% and an absolute reticulocyte count of 100 000/microlitre; 2) Hct of ≤ 30% and a) tachycardia (&gt; 180 beats/min) and tachypnoea (&gt; 70 breaths/min) persisting for 24 hours; or b) 3 or more episodes of apnoea or bradycardia in 24 hours, not due to other causes and not responsive to methylxanthine treatment; or c) average weight gain of &lt; 10 grams/day over a 1‐week period (infant tolerating full oral feed and receiving adequate calories); or d) undergoing surgery; 3) systemic infection associated with a sudden decrease in Hct. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were ordered by the clinicians caring for each infant without consulting the investigators. Written guidelines for erythrocyte transfusions were developed for the nursery 1 year before the start of the study. A copy of these guidelines was taped to the bed of each study infant. In general, babies who were otherwise well received transfusions only if they had a Hct &lt; 25% and signs referable to their anaemia, such as slowing in rate of growth, persistent severe tachycardia and tachypnoea, or worsening of episodes of apnoea and bradycardia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0028" title="ShannonKM , MentzerWC , AbelsRI , WertzM , Thayer‐MoriyamaJ , LiWY , et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. Journal of Pediatrics1992;120(4 Pt 1):586‐92. ">Shannon 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See <a href="./references#CD004868-bbs2-0027" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ShannonKM , MentzerWC , AbelsRI , FreemanP , NewtonN , ThompsonD , et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo‐controlled pilot study. Journal of Pediatrics1991;118(6):949‐55. [PUBMED: 2040933] ">Shannon 1991</a> above. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0029" title="BardH , WidnessJA . Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants. Journal of Pediatrics1995;127(3):478‐80. [PUBMED: 7544827] BaxterLM , VremanHJ , BallB , StevensonDK . Recombinant human erythropoietin (r‐HuEPO) increases total bilirubin production in premature infants. Clinical Pediatrics1995;34(4):213‐6. [DOI: 10.1177/000992289503400407; PUBMED: 7789015] BrownMS , ShapiroH . Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Journal of Pediatrics1996;128(4):512‐7. [PUBMED: 8618185] ShannonKM , KeithJF3rd , MentzerWC , EhrenkranzRA , BrownMS , WidnessJA , et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95(1):1‐8. [PUBMED: 7770284] WidnessJA , LombardKA , ZieglerEE , SerfassRE , CarlsonSJ , JohnsonKJ , et al. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin. Pediatric Research1997;41(3):416‐23. [DOI: 10.1203/00006450‐199703000‐00019; PUBMED: 9078545] ">Shannon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfuse infants at Hct ≤ 20%: a) if asymptomatic with reticulocytes &lt; 100 000/microlitre.</p> <p>Transfuse infants at Hct ≤ 30%: a) if receiving &lt; 35% supplemental hood oxygen, b) if on CPAP or mechanical ventilation with mean airway pressure &lt; 6 cm H<sub>2</sub>O, c) if significant apnoea and bradycardia are noted (9 episodes in 12 hours or 2 episodes in 24 hours requiring bag‐and‐mask ventilation) while receiving therapeutic doses of methylxanthines, d) if heart rate &gt; 180 beats/min or respiratory rate &gt; 80 breaths /min persists for 24 hours, e) if weight gain &lt; 10 grams/day is observed over 4 days while receiving ≥ 100 kcal/kg/day, f) if undergoing surgery. </p> <p>Transfuse for Hct ≤ 35%: a) if receiving &gt; 35% supplemental hood oxygen, b) if intubated on CPAP or mechanical ventilation with mean airway pressure ≥ 6 to 8 cm H<sub>2</sub>O. </p> <p>Do not transfuse: a) to replace blood removed for laboratory tests alone, b) for low Hct alone. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0030" title="WhitehallJS , PatoleSK , CampbellP . Recombinant human erythropoietin in anemia of prematurity. Indian Pediatrics1999;36(1):17‐27. [PUBMED: 10709119] ">Whitehall 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guidelines for red cell transfusions for anaemia of prematurity were based on the existing policy in the nursery, generally adopted by the neonatologists. They were as follows:<br/> I. Transfuse infants at Hb 80 g/L, (a) If reticulocyte count is &lt; 4% and (b) If receiving supplemental oxygen &gt; 30% or (c) If unexplained recurrent apnoea/bradycardia is noted (&gt; 1 to 2/hour) or (d) If persistent tachycardia (heart rate &gt; 170/min) or tachypnoea (respiratory rate &gt; 60/min) is noted, or (e) If there is failure to gain weight or successive weight loss on weekly recordings for 3 consecutive weeks. In absence of a clear evidence in the literature justifying red cell transfusions at a Hb of 80 g/L in otherwise asymptomatic neonates who are failing to thrive, it was decided that failure to gain weight or successive weight loss on weekly recordings for 3 consecutive weeks was a fair and substantial clinical indicator of the need to transfuse.<br/> II. Transfuse infants at Hb 100 g/L, (a) If receiving supplemental oxygen 30% and (b) needing intermittent mandatory ventilation or continuous positive airway pressure by nasal prongs for recurrent (&gt; 1 to 2 per hour), apnoea/bradycardia with saturations &lt; 90% on the pulse oximeter.<br/> III. Transfuse Infants at Hb 120 g/L, (a) If receiving mechanical ventilatory support with mean airway pressure 10 cm H<sub>2</sub>O and supplemental oxygen 30% during the acute phase of illness after birth. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0031" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm. Acta Neonatologica Japonica1999;35(4):755‐61. ">Yamada 1999a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conservative red blood cell transfusion guidelines were followed (details not presented, as we were unable to translate the information). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004868-bbs2-0032" title="YamadaM , TakahashiR , ChibaY , ItoT , NakaeN . Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm. Acta Neonatologica Japonica1999;35(4):762‐7. ">Yamada 1999b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conservative red blood cell transfusion guidelines were followed (details not presented, as we were unable to translate the information). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><sup>CPAP: continuous positive airways pressure<br/> FIO2: fraction of inspired oxygen<br/> H2O: water<br/> Hb: haemoglobin<br/> Hct: haematocrit</sup> </p> <p><sup>IMV: intermittent mandatory ventilation<br/> NICU: neonatal intensive care unit<br/> O2: oxygen</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Transfusion guidelines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/full#CD004868-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004868-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Late initiation of EPO (8‐28 days) vs. placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of one or more red blood cell transfusions (low and high dose of EPO) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.65, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Use of one or more red blood cell transfusions (high dose of EPO) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High dose iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.62, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low dose iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.67, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of one or more red blood cell transfusions (low dose of EPO) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.42, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 High dose of iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Low dose of iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.41, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total volume (mL/kg) of red blood cells transfused per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.61 [‐5.78, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of red blood cell transfusions per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.38, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of donors the infant was exposed to <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.20, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mortality during initial hospital stay (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.49, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Retinopathy of prematurity (all stages or stage not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.99, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Retinopathy of prematurity (stage ≥ 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.92, 3.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Proven sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.52, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Necrotising Enterocolitis ≥ Bell's stage 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.45, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Intraventricular haemorrhage all grades (or grade not specified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.53, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Bronchopulmonary dysplasia (supplementary oxygen at 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.00, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Bronchopulmonary dysplasia (supplementary oxygen at 36 weeks' postmenstrual age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.59, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 SIDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.25, 4.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.05, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.46, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐12.83, 12.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Use of one or more red blood cell transfusions (secondary analysis based on study quality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.65, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 HIgh quality studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.73, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Studies of uncertain quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.54, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Use of one or more red blood cell transfusions (secondary analysis based on RBC transfusion guidelines) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.67, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Strict RBC transfusion guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.69, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 No or less strict RBC guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.08, 0.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Late initiation of EPO (8‐28 days) vs. placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004868.pub6/references#CD004868-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004868.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004868-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004868-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD004868-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD004868-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD004868-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004868-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004868\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004868\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004868\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004868\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004868\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004868.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004868.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004868.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004868.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004868.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713838613"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004868.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713838616"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004868.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d600c5984936e',t:'MTc0MDcxMzgzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 